<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="63"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="59"><FilterOption id="762" count="32" label="Small molecule therapeutic"/><FilterOption id="585" count="27" label="Oral formulation"/><FilterOption id="595" count="20" label="Tablet formulation"/><FilterOption id="586" count="14" label="Capsule formulation"/><FilterOption id="761" count="13" label="Biological therapeutic"/><FilterOption id="648" count="13" label="Intravenous formulation"/><FilterOption id="751" count="10" label="Film coating"/><FilterOption id="573" count="10" label="Immunoglobulin-G"/><FilterOption id="740" count="10" label="Infusion"/><FilterOption id="85" count="9" label="Protein recombinant"/><FilterOption id="746" count="9" label="Solution"/><FilterOption id="647" count="8" label="Subcutaneous formulation"/><FilterOption id="898" count="6" label="Formulation powder"/><FilterOption id="166" count="5" label="Chimeric monoclonal antibody"/><FilterOption id="750" count="5" label="Freeze drying"/><FilterOption id="1263" count="4" label="Immuno-oncology"/><FilterOption id="169" count="4" label="Monoclonal antibody humanized"/><FilterOption id="128" count="3" label="Cell culture technique"/><FilterOption id="902" count="3" label="Orally disintegrating tablet"/><FilterOption id="766" count="3" label="Parenteral formulation unspecified"/><FilterOption id="1652" count="3" label="Prodrug"/><FilterOption id="180" count="2" label="Antibody fragment"/><FilterOption id="641" count="2" label="Controlled release formulation"/><FilterOption id="175" count="2" label="Drug combination"/><FilterOption id="596" count="2" label="Injectable formulation"/><FilterOption id="652" count="2" label="Intra-articular formulation"/><FilterOption id="764" count="2" label="Local formulation unspecified"/><FilterOption id="168" count="2" label="Monoclonal antibody human"/><FilterOption id="807" count="2" label="Monthly dosing"/><FilterOption id="661" count="2" label="Oral quick release formulation"/><FilterOption id="80" count="2" label="Peptide"/><FilterOption id="617" count="1" label="Aerosol formulation inhalant"/><FilterOption id="66" count="1" label="Antibiotic"/><FilterOption id="962" count="1" label="Biosimilar product"/><FilterOption id="127" count="1" label="Cell culture"/><FilterOption id="112" count="1" label="DNA technology"/><FilterOption id="749" count="1" label="Drying"/><FilterOption id="74" count="1" label="Glycoprotein"/><FilterOption id="616" count="1" label="Inhalant formulation"/><FilterOption id="851" count="1" label="Intradermal formulation"/><FilterOption id="651" count="1" label="Intramuscular formulation"/><FilterOption id="894" count="1" label="Liquid formulation"/><FilterOption id="170" count="1" label="Multivalent monoclonal antibody"/><FilterOption id="619" count="1" label="Nasal formulation local"/><FilterOption id="1647" count="1" label="Natural product"/><FilterOption id="620" count="1" label="Ophthalmic formulation"/><FilterOption id="593" count="1" label="Oral liquid formulation"/><FilterOption id="594" count="1" label="Oral suspension formulation"/><FilterOption id="600" count="1" label="Patch formulation"/><FilterOption id="348" count="1" label="PEGylated formulation"/><FilterOption id="618" count="1" label="Powder formulation inhalant"/><FilterOption id="83" count="1" label="Protein chimeric"/><FilterOption id="84" count="1" label="Protein fusion"/><FilterOption id="342" count="1" label="Receptor fusion"/><FilterOption id="899" count="1" label="Soluble receptor"/><FilterOption id="90" count="1" label="Steroid"/><FilterOption id="589" count="1" label="Sustained release formulation"/><FilterOption id="93" count="1" label="Toxin"/><FilterOption id="558" count="1" label="Transdermal formulation"/></Filter><Filter label="Indications" name="indications" total="53"><FilterOption id="337" count="6" label="Ulcerative colitis"/><FilterOption id="80" count="4" label="Coronary artery disease"/><FilterOption id="84" count="3" label="Crohns disease"/><FilterOption id="17" count="2" label="Anemia"/><FilterOption id="31" count="2" label="Asthma"/><FilterOption id="1542" count="2" label="Atrial fibrillation"/><FilterOption id="1185" count="2" label="Chronic obstructive pulmonary disease"/><FilterOption id="3251" count="2" label="End stage renal disease"/><FilterOption id="3246" count="2" label="Hormone refractory prostate cancer"/><FilterOption id="178" count="2" label="Hypertension"/><FilterOption id="189" count="2" label="Inflammatory bowel disease"/><FilterOption id="2466" count="2" label="Interstitial lung disease"/><FilterOption id="1828" count="2" label="Multiple myeloma"/><FilterOption id="1020" count="1" label="Acidosis"/><FilterOption id="1728" count="1" label="Acute lymphoblastic leukemia"/><FilterOption id="1731" count="1" label="Acute myelogenous leukemia"/><FilterOption id="1021" count="1" label="Alkalosis"/><FilterOption id="19" count="1" label="Anesthesia"/><FilterOption id="316" count="1" label="B-cell lymphoma"/><FilterOption id="3443" count="1" label="Bone resorption"/><FilterOption id="55" count="1" label="Cardiac failure"/><FilterOption id="2659" count="1" label="Diabetic macular edema"/><FilterOption id="100" count="1" label="Diabetic nephropathy"/><FilterOption id="1749" count="1" label="Diffuse large B-cell lymphoma"/><FilterOption id="3366" count="1" label="Essential hypertension"/><FilterOption id="1745" count="1" label="Follicle center lymphoma"/><FilterOption id="626" count="1" label="Heart disease"/><FilterOption id="1767" count="1" label="Hepatocellular carcinoma"/><FilterOption id="1003" count="1" label="Hyperphosphatemia"/><FilterOption id="472" count="1" label="Hypothermia"/><FilterOption id="3771" count="1" label="Idiopathic pulmonary fibrosis"/><FilterOption id="3455" count="1" label="Influenza virus A infection"/><FilterOption id="56" count="1" label="Ischemic heart disease"/><FilterOption id="1078" count="1" label="Lung embolism"/><FilterOption id="4250" count="1" label="Metastatic renal cell carcinoma"/><FilterOption id="210" count="1" label="Migraine"/><FilterOption id="3679" count="1" label="Migraine with aura"/><FilterOption id="3680" count="1" label="Migraine without aura"/><FilterOption id="224" count="1" label="Myocardial infarction"/><FilterOption id="1295" count="1" label="Neuropathic pain"/><FilterOption id="319" count="1" label="Non-Hodgkin lymphoma"/><FilterOption id="837" count="1" label="Non-insulin dependent diabetes"/><FilterOption id="1640" count="1" label="Occlusive coronary artery disease"/><FilterOption id="245" count="1" label="Osteoarthritis"/><FilterOption id="20" count="1" label="Pain"/><FilterOption id="360" count="1" label="Pneumonia"/><FilterOption id="1781" count="1" label="Psoriatic arthritis"/><FilterOption id="1867" count="1" label="Pulmonary hypertension"/><FilterOption id="286" count="1" label="Renal disease"/><FilterOption id="3663" count="1" label="Resistant hypertension"/><FilterOption id="330" count="1" label="Restenosis"/><FilterOption id="291" count="1" label="Rheumatoid arthritis"/><FilterOption id="735" count="1" label="Toxicity"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="15907" count="6" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="2622" count="5" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="2704" count="4" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)"/><FilterOption id="6407" count="4" label="Crohns disease - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="2492" count="3" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="2619" count="3" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"/><FilterOption id="2623" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"/><FilterOption id="2703" count="3" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="6339" count="3" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"/><FilterOption id="40" count="3" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"/><FilterOption id="44" count="3" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Trough DBP"/><FilterOption id="261" count="3" label="Hypertension - Assessment of Safety and Tolerability"/><FilterOption id="25" count="3" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP"/><FilterOption id="29" count="3" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Trough SBP"/><FilterOption id="7538" count="3" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="7680" count="3" label="Lymphoma - Assessment of adverse events"/><FilterOption id="15936" count="3" label="Ulcerative colitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="17273" count="2" label="Anemia - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="17356" count="2" label="Anemia - Assessment of adverse events"/><FilterOption id="6005" count="2" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide"/><FilterOption id="6000" count="2" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Blood eosinophils"/><FilterOption id="6111" count="2" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)"/><FilterOption id="27645" count="2" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control test (ACT)"/><FilterOption id="9509" count="2" label="Atrial fibrillation - Assessment of Hemorrhagic Complications"/><FilterOption id="2491" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events"/><FilterOption id="2654" count="2" label="Coronary artery disease - Assessment of Hemorrhagic Complications - Major/minor bleeding"/><FilterOption id="43282" count="2" label="Coronary artery disease - Assessment of Safety and Tolerability"/><FilterOption id="2551" count="2" label="Coronary artery disease - Assessment of Stenosis/Restenosis - In-segment late loss/In-lesion late loss"/><FilterOption id="2749" count="2" label="Coronary artery disease - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment"/><FilterOption id="2518" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis (Definite /Probable /Possible)"/><FilterOption id="2565" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis"/><FilterOption id="6309" count="2" label="Crohns disease - Assessment of Clinical Response"/><FilterOption id="6406" count="2" label="Crohns disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="6439" count="2" label="Crohns disease - Assessment of Safety and Tolerability"/><FilterOption id="6471" count="2" label="Crohns disease - Protocol Specified Other Endpoints"/><FilterOption id="11329" count="2" label="Diabetic complication - Assessment of Adverse Events"/><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"/><FilterOption id="22506" count="2" label="End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)"/><FilterOption id="22596" count="2" label="End stage renal disease - Assessment of Mortality/Death Rates"/><FilterOption id="22553" count="2" label="End stage renal disease - Assessment of Serum Electrolytes - Assessment of calcium"/><FilterOption id="22552" count="2" label="End stage renal disease - Assessment of Serum Electrolytes - Assessment of phosphate"/><FilterOption id="22595" count="2" label="End stage renal disease - Assessment of adverse events"/><FilterOption id="22543" count="2" label="End stage renal disease - Assessment of lipid profiles"/><FilterOption id="115" count="2" label="Hypertension - Assessment of Electrocardiography (ECG) Findings"/><FilterOption id="7558" count="2" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7089" count="2" label="Prostate tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="7088" count="2" label="Prostate tumor - Assessment of Disease Progression"/><FilterOption id="7152" count="2" label="Prostate tumor - Assessment of Other Prostate Specific Markers"/><FilterOption id="7129" count="2" label="Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables"/><FilterOption id="7189" count="2" label="Prostate tumor - Assessment of Safety and Tolerability"/><FilterOption id="7207" count="2" label="Prostate tumor - Assessment of Skeletal Related Events"/><FilterOption id="7062" count="2" label="Prostate tumor - Assessment of Survival - Assessment of median survival"/><FilterOption id="9126" count="2" label="Prostate tumor - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate"/><FilterOption id="15881" count="2" label="Ulcerative colitis - Assessment of Clinical Response"/><FilterOption id="15950" count="2" label="Ulcerative colitis - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="15894" count="2" label="Ulcerative colitis - Assessment of Remission - Assessment of proportion of patients in remission"/><FilterOption id="15890" count="2" label="Ulcerative colitis - Assessment of Remission - Assessment of steroid-free remission"/><FilterOption id="15934" count="2" label="Ulcerative colitis - Assessment of use of Rescue Medication - Assessment by steroid/immunosuppressant use"/><FilterOption id="15971" count="2" label="Ulcerative colitis - Protocol Specified Other Endpoints"/><FilterOption id="3082" count="1" label="Acute coronary syndrome - Assessment of Stents Related Events"/><FilterOption id="2940" count="1" label="Acute coronary syndrome - Assessment of Therapy Related Outcomes - Efficacy parameters"/><FilterOption id="2941" count="1" label="Acute coronary syndrome - Assessment of Therapy Related Outcomes - Safety parameters"/><FilterOption id="17257" count="1" label="Anemia - Assessment of Cardiac Function"/><FilterOption id="17267" count="1" label="Anemia - Assessment of Co-morbidity - Assessment of cardiac diseases/disorders"/><FilterOption id="17363" count="1" label="Anemia - Assessment of Mortality/Death Rates"/><FilterOption id="17334" count="1" label="Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="17357" count="1" label="Anemia - Assessment of Safety and Tolerability - Assessment of serious adverse events"/><FilterOption id="17324" count="1" label="Anemia - Assessment of Therapy Related Outcomes - Assessment of efficacy"/><FilterOption id="17321" count="1" label="Anemia - Assessment of Therapy Related Outcomes - Assessment of treatment utilization/alterations"/><FilterOption id="17255" count="1" label="Anemia - Assessment of Vital Signs"/><FilterOption id="17253" count="1" label="Anemia - Clinical Assessments"/><FilterOption id="17294" count="1" label="Anemia - Hematological Assessments - Assessment of hemoglobin response"/><FilterOption id="17220" count="1" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"/><FilterOption id="6081" count="1" label="Asthma - Assessment of Clinical Response - Assessment of time to treatment failure (TTF)"/><FilterOption id="5985" count="1" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"/><FilterOption id="5986" count="1" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"/><FilterOption id="5987" count="1" label="Asthma - Assessment of Exacerbations - Time to first exacerbation"/><FilterOption id="5941" count="1" label="Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1"/><FilterOption id="5944" count="1" label="Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1"/><FilterOption id="6009" count="1" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum immunoglobulins"/><FilterOption id="6083" count="1" label="Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="37469" count="1" label="Asthma - Health Economic Assessments - Health Services Utilization"/><FilterOption id="6110" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma Quality of Life Questionnaire (AQLQ)"/><FilterOption id="26737" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Mini asthma quality of life questionnaire (MiniAQLQ)"/><FilterOption id="9492" count="1" label="Atrial fibrillation - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction"/><FilterOption id="9504" count="1" label="Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of ischemic stroke"/><FilterOption id="9510" count="1" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"/><FilterOption id="9439" count="1" label="Atrial fibrillation - Assessment of Mortality/Death Rates - Assessment of cardiovascular death"/><FilterOption id="9437" count="1" label="Atrial fibrillation - Assessment of Mortality/Death Rates"/><FilterOption id="9645" count="1" label="Atrial fibrillation - Assessment of Safety and Tolerability"/><FilterOption id="9630" count="1" label="Atrial fibrillation - Assessment of Therapy Related Outcomes"/><FilterOption id="9520" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of stent thrombosis"/><FilterOption id="9519" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"/><FilterOption id="9516" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events"/><FilterOption id="9646" count="1" label="Atrial fibrillation - Assessment of adverse events"/><FilterOption id="45399" count="1" label="Atrial fibrillation - Imaging/Radiological Assessments"/><FilterOption id="9676" count="1" label="Atrial fibrillation - Protocol Specified Other Endpoints - Assessment of prescription changes/rescue medication uses"/><FilterOption id="9666" count="1" label="Atrial fibrillation - Protocol Specified Other Endpoints"/><FilterOption id="654" count="1" label="Cardiac failure - Assessment of Cardiac Markers - Plasma B-type natriuretic peptide (BNP)"/><FilterOption id="1029" count="1" label="Cardiac failure - Assessment of Cardiovascular Events - Cardiovascular intervention/surgery"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="4"><FilterOption id="L" count="33" label="Launched"/><FilterOption id="C3" count="6" label="Phase 3 Clinical"/><FilterOption id="DX" count="3" label="Discontinued"/><FilterOption id="C2" count="2" label="Phase 2 Clinical"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="57"><FilterOption id="14881" count="7" label="Boehringer Ingelheim International GmbH"/><FilterOption id="22546" count="5" label="Boehringer Ingelheim GmbH"/><FilterOption id="1103352" count="4" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"/><FilterOption id="22563" count="4" label="Boehringer Ingelheim Ltd"/><FilterOption id="16450" count="4" label="Gilead Sciences Inc"/><FilterOption id="1143376" count="4" label="Gilead Sciences Singapore Pte Ltd"/><FilterOption id="1076492" count="4" label="HOSPITAL DE GALDACANO"/><FilterOption id="1038736" count="4" label="PETHEMA Foundation"/><FilterOption id="19446" count="4" label="Roche Holding AG"/><FilterOption id="22545" count="3" label="Boehringer Ingelheim AB"/><FilterOption id="18767" count="3" label="Pfizer Inc"/><FilterOption id="1122528" count="3" label="SCS Boehringer Ingelheim Comm.V"/><FilterOption id="13601" count="2" label="Abbott Laboratories"/><FilterOption id="22556" count="2" label="Boehringer Ingelheim France SARL"/><FilterOption id="22590" count="2" label="Boehringer Ingelheim SA"/><FilterOption id="15331" count="2" label="Celgene Corp"/><FilterOption id="26178" count="2" label="F Hoffmann-La Roche AG"/><FilterOption id="1069025" count="2" label="Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa"/><FilterOption id="1039423" count="2" label="Hospital Clinic of Barcelona"/><FilterOption id="1079012" count="2" label="Hospital de Galdakao"/><FilterOption id="14042" count="1" label="Allergan Inc"/><FilterOption id="20972" count="1" label="Astellas Pharma Europe Ltd"/><FilterOption id="14455" count="1" label="Bayer AG"/><FilterOption id="1094314" count="1" label="Biosensors Europe SA"/><FilterOption id="1018917" count="1" label="Biotronik VI Patent AG"/><FilterOption id="22553" count="1" label="Boehringer Ingelheim A/S"/><FilterOption id="22549" count="1" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="22554" count="1" label="Boehringer Ingelheim BV"/><FilterOption id="22586" count="1" label="Boehringer Ingelheim Corp"/><FilterOption id="22555" count="1" label="Boehringer Ingelheim Ellas AE"/><FilterOption id="22560" count="1" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="1077096" count="1" label="EuroCTO Club"/><FilterOption id="1086388" count="1" label="foundation Senefro"/><FilterOption id="1093964" count="1" label="Fundacion Interhospitalaria para la Investigacion Cardiovascular"/><FilterOption id="1046327" count="1" label="Fundacion Renal Inigo Alvarez De Toledo"/><FilterOption id="1161122" count="1" label="Fundación EPIC"/><FilterOption id="1064566" count="1" label="Fundación Instituto De Estudios De Ciencias De La Salud De Castilla Y León"/><FilterOption id="1082416" count="1" label="Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular"/><FilterOption id="1051308" count="1" label="Fundación Para La Investigación Biomédica Del Hospital De La Princesa"/><FilterOption id="1024529" count="1" label="Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañon"/><FilterOption id="19453" count="1" label="Genentech Inc"/><FilterOption id="1042252" count="1" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="1040862" count="1" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="1086209" count="1" label="Hospital Valme"/><FilterOption id="1153001" count="1" label="Klinera Corporation India"/><FilterOption id="1055006" count="1" label="Ministry of Health, Spain"/><FilterOption id="1099505" count="1" label="Osakidetza"/><FilterOption id="1048099" count="1" label="Queen Mary Hospital"/><FilterOption id="1003618" count="1" label="Reata Pharmaceuticals Inc"/><FilterOption id="1090417" count="1" label="Roche Singapore Pte Ltd"/><FilterOption id="16299" count="1" label="Sanofi Genzyme"/><FilterOption id="1077534" count="1" label="Sociedad Española de Neumología y Cirugía Torácica"/><FilterOption id="1053159" count="1" label="Spanish Foundation of Rheumatology"/><FilterOption id="1073757" count="1" label="Spanish Society of Cardiology"/><FilterOption id="1044204" count="1" label="Terumo Europe NV"/><FilterOption id="22598" count="1" label="Unilfarma Lda"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="5"><FilterOption id="4" count="33" label="Completed"/><FilterOption id="2" count="15" label="Recruiting"/><FilterOption id="6" count="6" label="Terminated"/><FilterOption id="1" count="5" label="Not yet recruiting"/><FilterOption id="3" count="4" label="No longer recruiting"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="NO" count="35" label="No"/><FilterOption id="YES" count="28" label="Yes"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="6"><FilterOption id="1731" count="1" label="Acute myelogenous leukemia"/><FilterOption id="3443" count="1" label="Bone resorption"/><FilterOption id="100" count="1" label="Diabetic nephropathy"/><FilterOption id="189" count="1" label="Inflammatory bowel disease"/><FilterOption id="1640" count="1" label="Occlusive coronary artery disease"/><FilterOption id="337" count="1" label="Ulcerative colitis"/></Filter><Filter label="Registry Id" name="trialRegistries" total="14"><FilterOption id="1000" count="63" label="CT.gov"/><FilterOption id="1001" count="34" label="EudraCT"/><FilterOption id="1030" count="7" label="RSRM CTR"/><FilterOption id="1021" count="6" label="NMRR"/><FilterOption id="1035" count="6" label="Singapore HSA CTR"/><FilterOption id="1012" count="4" label="CTRI"/><FilterOption id="1019" count="4" label="DRKS"/><FilterOption id="1023" count="4" label="UKCRN"/><FilterOption id="1006" count="3" label="JapicCTI"/><FilterOption id="1018" count="3" label="SLCTR"/><FilterOption id="1009" count="2" label="HKClinicalTrials.com"/><FilterOption id="1039" count="1" label="CDE"/><FilterOption id="1033" count="1" label="Mexico CTR"/><FilterOption id="1004" count="1" label="WHO ICTRP"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="4"><FilterOption id="4" count="2" label="Other"/><FilterOption id="5" count="2" label="Patient Enrollment Issues"/><FilterOption id="2" count="1" label="Not Reported"/><FilterOption id="7" count="1" label="Safety Issues"/></Filter><Filter label="Active Controls" name="trialActiveControls" total="10"><FilterOption id="2836" count="2" label="clopidogrel"/><FilterOption id="53547" count="1" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="15954" count="1" label="bortezomib"/><FilterOption id="7413" count="1" label="darbepoetin alfa"/><FilterOption id="8121" count="1" label="epoetin beta, Roche"/><FilterOption id="6850" count="1" label="infliximab"/><FilterOption id="4196" count="1" label="ramipril"/><FilterOption id="8050" count="1" label="thalidomide, Celgene"/><FilterOption id="36332" count="1" label="ticagrelor"/><FilterOption id="44375" count="1" label="warfarin"/></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="17519" count="4" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="167" count="4" label="Hypertension - Subjects co-morbid with renal disease/disorder"/><FilterOption id="16" count="4" label="Hypertension - Subjects with Secondary Hypertension - Subjects with unilateral or bilateral renal artery stenosis"/><FilterOption id="17521" count="3" label="End stage renal disease - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="17531" count="3" label="End stage renal disease - Subjects co-morbid with infections"/><FilterOption id="17553" count="3" label="End stage renal disease - Subjects with Contraindications to Study Procedure"/><FilterOption id="17533" count="3" label="End stage renal disease - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="17541" count="3" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"/><FilterOption id="195" count="3" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with aortic stenosis"/><FilterOption id="269" count="3" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with cardiomyopathy"/><FilterOption id="223" count="3" label="Hypertension - Subjects with Electrolyte Imbalances - Hyperkalemia"/><FilterOption id="224" count="3" label="Hypertension - Subjects with Electrolyte Imbalances - Hyponatremia"/><FilterOption id="130" count="3" label="Hypertension - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/contraindication to angiotensin II receptor blockers"/><FilterOption id="129" count="3" label="Hypertension - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to ACE inhibitors"/><FilterOption id="13" count="3" label="Hypertension - Subjects with Secondary Hypertension - Subjects with primary aldosteronism"/><FilterOption id="197" count="3" label="Hypertension - Subjects with Valvular Heart Diseases - Mitral stenosis"/><FilterOption id="13170" count="3" label="Ulcerative colitis - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="13152" count="3" label="Ulcerative colitis - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/><FilterOption id="11817" count="2" label="Anemia - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="11793" count="2" label="Anemia - Subjects with specific disease - Subjects with Hemolytic Anemia"/><FilterOption id="3839" count="2" label="Asthma - Subjects co-morbid with Respiratory Diseases/Disorders"/><FilterOption id="20245" count="2" label="Asthma - Subjects co-morbid with infections"/><FilterOption id="3951" count="2" label="Asthma - Subjects with Asthma Exacerbations"/><FilterOption id="5667" count="2" label="Asthma - Subjects with specific cigarette smoking activity - Ex-smokers"/><FilterOption id="3058" count="2" label="Chronic obstructive pulmonary disease - Subjects co-morbid with Respiratory Diseases/Disorders"/><FilterOption id="1941" count="2" label="Coronary artery disease - Protocol Specified Other Exclusion Criteria - Small life expectancy"/><FilterOption id="1657" count="2" label="Coronary artery disease - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with cardiogenic shock"/><FilterOption id="1651" count="2" label="Coronary artery disease - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="1842" count="2" label="Coronary artery disease - Subjects with History of/Scheduled for Diagnostic/Therapeutic Procedures"/><FilterOption id="1884" count="2" label="Coronary artery disease - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Anticoagulation /antiplatelet /anti-thrombotic"/><FilterOption id="4432" count="2" label="Crohns disease - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="4456" count="2" label="Crohns disease - Subjects with Protocol Specified Compliance Status - Patient unable or unwilling to comply with protocol"/><FilterOption id="4465" count="2" label="Crohns disease - Subjects with history of psychiatric disease/disorder - Subjects with history of drug/substance abuse"/><FilterOption id="8609" count="2" label="Diabetic complication - Subjects with Abnormal Laboratory Findings"/><FilterOption id="17525" count="2" label="End stage renal disease - Subjects co-morbid with Endocrine/Metabolic Disorders - Subjects co-morbid with diabetes mellitus"/><FilterOption id="17529" count="2" label="End stage renal disease - Subjects co-morbid with Hematological/Coagulation Disorders - Subjects co-morbid with anemia"/><FilterOption id="17528" count="2" label="End stage renal disease - Subjects co-morbid with Hematological/Coagulation Disorders"/><FilterOption id="17522" count="2" label="End stage renal disease - Subjects co-morbid with hepatobiliary disorders/diseases"/><FilterOption id="17511" count="2" label="End stage renal disease - Subjects co-morbid with renal disease/disorder - Subjects with acute renal failure"/><FilterOption id="17551" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Intervention/Surgery"/><FilterOption id="17537" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy - Subjects with protocol specified dialysis related criteria"/><FilterOption id="17539" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy - Subjects with protocol specified transplantation related criteria"/><FilterOption id="17536" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy"/><FilterOption id="46" count="2" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with unstable/variant angina"/><FilterOption id="47" count="2" label="Hypertension - Subjects co-morbid with heart disorders/diseases - Subjects co-morbid with myocardial infarction"/><FilterOption id="266" count="2" label="Hypertension - Subjects with Co-morbid Conditions - Subjects co-morbid with Angioedema"/><FilterOption id="84" count="2" label="Hypertension - Subjects with Current/History of Antihypertensive Treatment"/><FilterOption id="140" count="2" label="Hypertension - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="1007" count="2" label="Non-insulin dependent diabetes - Subjects with Protocol Specified Reproductive Status - Pregnant/lactating women"/><FilterOption id="20125" count="2" label="Pain - Subjects with Hypersensitivity/Contraindication to Device/Procedures"/><FilterOption id="4968" count="2" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects on prior/concurrent radiotherapy"/><FilterOption id="4967" count="2" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="4975" count="2" label="Prostate tumor - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="13128" count="2" label="Ulcerative colitis - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="13142" count="2" label="Ulcerative colitis - Subjects with Abnormal Laboratory Findings"/><FilterOption id="13118" count="2" label="Ulcerative colitis - Subjects with Complications of Ulcerative Colitis - Subjects with toxic megacolon"/><FilterOption id="13158" count="2" label="Ulcerative colitis - Subjects with History of/Current Use of a Prohibited Medication - Subjects with a history/current use of protocol prohibited biologicals"/><FilterOption id="13157" count="2" label="Ulcerative colitis - Subjects with History of/Current Use of a Prohibited Medication - Subjects with a history/current use of protocol prohibited glucorticoid/steroid"/><FilterOption id="13167" count="2" label="Ulcerative colitis - Subjects with Protocol Specified Compliance Status - Patient unable/unwilling to comply with protocol"/><FilterOption id="13107" count="2" label="Ulcerative colitis - Subjects with Severe to Fulminant Ulcerative Colitis"/><FilterOption id="13173" count="2" label="Ulcerative colitis - Subjects with history of psychiatric disease/disorder - Subjects with history of drug/substance abuse"/><FilterOption id="2102" count="1" label="Acute coronary syndrome - Subjects co-morbid with Hematological/Coagulation Disorders"/><FilterOption id="2000" count="1" label="Acute coronary syndrome - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with cardiogenic shock"/><FilterOption id="1997" count="1" label="Acute coronary syndrome - Subjects co-morbid with heart disorders/diseases"/><FilterOption id="2195" count="1" label="Acute coronary syndrome - Subjects with History of Other Procedure/Intervention"/><FilterOption id="2179" count="1" label="Acute coronary syndrome - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/><FilterOption id="1964" count="1" label="Acute coronary syndrome - Subjects with Myocardial Infarction (MI) - Acute unstabilized ST segment elevation myocardial infarction (STEMI)"/><FilterOption id="2240" count="1" label="Acute coronary syndrome - Subjects with Specific Coronary Angiographic Findings - Target lesion involving side branches"/><FilterOption id="1967" count="1" label="Acute coronary syndrome - Subjects with Specific Coronary Angiographic Findings"/><FilterOption id="2154" count="1" label="Acute coronary syndrome - Subjects with history of cardiac intervention /coronary revascularization - Aortocoronary bypass-surgery"/><FilterOption id="2153" count="1" label="Acute coronary syndrome - Subjects with history of cardiac intervention /coronary revascularization"/><FilterOption id="11822" count="1" label="Anemia - Subjects co-morbid with endocrine/metabolic diseases/disorders"/><FilterOption id="11824" count="1" label="Anemia - Subjects co-morbid with inflammatory disorders"/><FilterOption id="11777" count="1" label="Anemia - Subjects co-morbid with renal disease/disorder - Subjects on dialysis"/><FilterOption id="11844" count="1" label="Anemia - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable liver function"/><FilterOption id="11835" count="1" label="Anemia - Subjects with Abnormal/Unacceptable Clinical Assessments"/><FilterOption id="11780" count="1" label="Anemia - Subjects with Aplastic Anemia"/><FilterOption id="11825" count="1" label="Anemia - Subjects with Co-morbid Conditions - Subjects co-morbid with hematological disease/disorders"/><FilterOption id="11823" count="1" label="Anemia - Subjects with Co-morbid Conditions - Subjects with premalignant/malignant condition"/><FilterOption id="11815" count="1" label="Anemia - Subjects with Co-morbid Conditions"/><FilterOption id="11802" count="1" label="Anemia - Subjects with History of/Scheduled for Intervention/Surgery"/><FilterOption id="11864" count="1" label="Anemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of blood donation/transfusions"/><FilterOption id="11853" count="1" label="Anemia - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"/><FilterOption id="11788" count="1" label="Anemia - Subjects with Sickle Cell Anemia"/><FilterOption id="11871" count="1" label="Anemia - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="20256" count="1" label="Asthma - Protocol Specified Other Exclusion Criteria"/><FilterOption id="20255" count="1" label="Asthma - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="20249" count="1" label="Asthma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for asthma drugs"/><FilterOption id="24795" count="1" label="Asthma - Subjects with Protocol Specified Participation Status - Subjects with prior/current participation in any investigational study"/><FilterOption id="24794" count="1" label="Asthma - Subjects with Protocol Specified Reproductive Status - Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception"/><FilterOption id="3954" count="1" label="Asthma - Subjects with specific cigarette smoking activity - Smokers"/><FilterOption id="7194" count="1" label="Atrial fibrillation - Subjects co-morbid with Hematological/Coagulation Disorders - Subjects co-morbid with severe anemia"/><FilterOption id="7196" count="1" label="Atrial fibrillation - Subjects co-morbid with Hematological/Coagulation Disorders - Subjects co-morbid with thrombocytopenia"/><FilterOption id="7169" count="1" label="Atrial fibrillation - Subjects co-morbid with Hepatic Disorders/Diseases"/><FilterOption id="7199" count="1" label="Atrial fibrillation - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="7174" count="1" label="Atrial fibrillation - Subjects co-morbid with renal disease/disorder"/><FilterOption id="7402" count="1" label="Atrial fibrillation - Subjects with History of Cerebrovascular Events - Subjects with history of stroke"/><FilterOption id="7259" count="1" label="Atrial fibrillation - Subjects with Prior Cardiac Intervention - Subjects with prior mechanical valve repair"/><FilterOption id="25438" count="1" label="Atrial fibrillation - Subjects with Protocol Specified Participation Status"/><FilterOption id="1405" count="1" label="Cardiac failure - Protocol Specified Other Exclusion Criteria - Language or cultural barriers (Inability to read/Speak)"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="20"><FilterOption count="2" label="201604"/><FilterOption count="2" label="201803"/><FilterOption count="1" label="200905"/><FilterOption count="1" label="201103"/><FilterOption count="1" label="201105"/><FilterOption count="1" label="201202"/><FilterOption count="1" label="201210"/><FilterOption count="1" label="201301"/><FilterOption count="1" label="201402"/><FilterOption count="1" label="201410"/><FilterOption count="1" label="201502"/><FilterOption count="1" label="201601"/><FilterOption count="1" label="201603"/><FilterOption count="1" label="201609"/><FilterOption count="1" label="201612"/><FilterOption count="1" label="201706"/><FilterOption count="1" label="201709"/><FilterOption count="1" label="201805"/><FilterOption count="1" label="201903"/><FilterOption count="1" label="201904"/></Filter><Filter label="Funder Type" name="trialFunderType" total="2"><FilterOption id="CMP" count="44" label="Company"/><FilterOption id="ACA" count="27" label="Academic"/></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="62" label="Northern, Southern &amp; Western Europe"/><FilterOption id="EEUR" count="24" label="Eastern Europe"/><FilterOption id="USCA" count="16" label="US &amp; Canada"/><FilterOption id="EAPO" count="14" label="East Asia &amp; Pacific Ocean"/><FilterOption id="AUNZ" count="13" label="Australia &amp; New Zealand"/><FilterOption id="MENA" count="12" label="Middle East &amp; North Africa"/><FilterOption id="CSAF" count="10" label="Central &amp; Southern Africa"/><FilterOption id="SOAM" count="10" label="South America"/><FilterOption id="CAAC" count="8" label="Central America &amp; Caribbean"/><FilterOption id="SOCA" count="5" label="Southern &amp; Central Asia"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="34" count="3" label="Hypertension - Subjects on Hypertensive Treatment"/><FilterOption id="8784" count="3" label="Ulcerative colitis - Subjects with Active Ulcerative Colitis"/><FilterOption id="7511" count="2" label="Anemia - Subjects with History of/Scheduled for Disease Specific Therapy - Subjects on dialysis"/><FilterOption id="11962" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma"/><FilterOption id="7204" count="2" label="Atrial fibrillation - Subjects with Nonvalvular Atrial Fibrillation"/><FilterOption id="201" count="2" label="Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)"/><FilterOption id="245" count="2" label="Coronary artery disease - Subjects with Abnormal Angiographic Findings - De novo lesion/lesions"/><FilterOption id="368" count="2" label="Coronary artery disease - Subjects with Myocardial Ischemia"/><FilterOption id="3426" count="2" label="Crohns disease - Subjects with Treatment Resistant Disease"/><FilterOption id="3424" count="2" label="Crohns disease - Treatment Naive Subjects"/><FilterOption id="7702" count="2" label="End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)"/><FilterOption id="7716" count="2" label="End stage renal disease - Subjects with Anemia of Chronic Kidney Disease"/><FilterOption id="7717" count="2" label="End stage renal disease - Subjects with Electrolyte Imbalance/Associated Complications"/><FilterOption id="7701" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 4 chronic kidney disease"/><FilterOption id="5" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 1 (JNC 6) hypertension"/><FilterOption id="6" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension"/><FilterOption id="1" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension"/><FilterOption id="11" count="2" label="Hypertension - Subjects with Refractory/Resistant/Uncontrolled Hypertension"/><FilterOption id="3472" count="2" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="3473" count="2" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="3489" count="2" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"/><FilterOption id="3502" count="2" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"/><FilterOption id="3500" count="2" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"/><FilterOption id="3501" count="2" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"/><FilterOption id="3870" count="2" label="Multiple myeloma - Subjects with Symptomatic Disease"/><FilterOption id="110" count="2" label="Non-insulin dependent diabetes - Subjects with Diabetic Complications"/><FilterOption id="3583" count="2" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"/><FilterOption id="3571" count="2" label="Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with progressive disease despite therapy"/><FilterOption id="3586" count="2" label="Prostate tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="8775" count="2" label="Ulcerative colitis - Subjects with Mild to Moderate Ulcerative Colitis"/><FilterOption id="8792" count="2" label="Ulcerative colitis - Subjects with Treatment Resistant Disease"/><FilterOption id="8787" count="2" label="Ulcerative colitis - Treatment Naive Subjects"/><FilterOption id="302" count="1" label="Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects"/><FilterOption id="362" count="1" label="Acute coronary syndrome - Subjects with Abnormal Angiographic Findings - Stenosis/Narrowing of vessel"/><FilterOption id="292" count="1" label="Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI)"/><FilterOption id="321" count="1" label="Acute coronary syndrome - Subjects with History of Cardiac Intervention"/><FilterOption id="11963" count="1" label="Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs"/><FilterOption id="3313" count="1" label="Asthma - Subjects with Levels of Asthma Control - Subjects with uncontrolled asthma"/><FilterOption id="59" count="1" label="Cardiac failure - Acute Decompensated Heart Failure (ADHF) Subjects"/><FilterOption id="72" count="1" label="Cardiac failure - Chronic Heart Failure Subjects"/><FilterOption id="61" count="1" label="Cardiac failure - Subjects with Symptomatic Disease"/><FilterOption id="556" count="1" label="Chronic obstructive pulmonary disease - Subjects with Stable COPD"/><FilterOption id="557" count="1" label="Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease"/><FilterOption id="565" count="1" label="Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections"/><FilterOption id="564" count="1" label="Chronic obstructive pulmonary disease - Subjects with disease related complications"/><FilterOption id="207" count="1" label="Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention"/><FilterOption id="369" count="1" label="Coronary artery disease - Subjects on /Indicated for/History of Cardiovascular Therapy"/><FilterOption id="249" count="1" label="Coronary artery disease - Subjects with Abnormal Angiographic Findings - Stenosis or lesion of all coronary arteries or its principal branches"/><FilterOption id="251" count="1" label="Coronary artery disease - Subjects with Abnormal Angiographic Findings - Stenosis/Narrowing of vessel"/><FilterOption id="243" count="1" label="Coronary artery disease - Subjects with Abnormal Angiographic Findings"/><FilterOption id="188" count="1" label="Coronary artery disease - Subjects with Angina - Subjects with Stable Angina"/><FilterOption id="182" count="1" label="Coronary artery disease - Subjects with Angina"/><FilterOption id="367" count="1" label="Coronary artery disease - Subjects with Stable Coronary Artery Disease"/><FilterOption id="174" count="1" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)"/><FilterOption id="178" count="1" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)"/><FilterOption id="173" count="1" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease"/><FilterOption id="3410" count="1" label="Crohns disease - Crohns Disease Subjects with Specific Disease Patterns - Luminal crohns disease"/><FilterOption id="3407" count="1" label="Crohns disease - Crohns Disease Subjects with Specific Disease Patterns - Penetrating/fistulising crohns disease"/><FilterOption id="11841" count="1" label="Crohns disease - Others - Healthy Subjects"/><FilterOption id="3404" count="1" label="Crohns disease - Subjects with Active Crohns Disease"/><FilterOption id="3405" count="1" label="Crohns disease - Subjects with Crohns Disease in Remission"/><FilterOption id="3425" count="1" label="Crohns disease - Subjects with H/O Treatment with Crohns Disease Medication"/><FilterOption id="3427" count="1" label="Crohns disease - Subjects with History of Surgical Intervention"/><FilterOption id="3754" count="1" label="Crohns disease - Subjects with Moderate to Severe Crohns Disease"/><FilterOption id="8454" count="1" label="Diabetic complication - Subjects with Diabetic Macular Edema"/><FilterOption id="8443" count="1" label="Diabetic complication - Subjects with Diabetic Nephropathy"/><FilterOption id="7708" count="1" label="End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy"/><FilterOption id="7704" count="1" label="End stage renal disease - Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)"/><FilterOption id="11418" count="1" label="End stage renal disease - Subjects with Electrolyte Imbalance/Associated Complications - Subjects with bone complications"/><FilterOption id="7698" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 1 chronic kidney disease"/><FilterOption id="7699" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease"/><FilterOption id="7700" count="1" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"/><FilterOption id="11420" count="1" label="End stage renal disease - Subjects with Proteinuria/Albuminuria"/><FilterOption id="7718" count="1" label="End stage renal disease - Subjects with comorbid conditions - Subjects co-morbid with secondary hyperparathyroidism"/><FilterOption id="16345" count="1" label="Hepatobiliary system tumor - Subjects with specific disease - Subjects with hepatocellular carcinoma"/><FilterOption id="10767" count="1" label="Herpesvirus infection - Subjects with Epstein-Barr Virus Infections - Subjects with lymphoma/lymphoproliferative disorders"/><FilterOption id="19022" count="1" label="HIV infection - Subjects with HIV Infection"/><FilterOption id="3" count="1" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with diastolic hypertension"/><FilterOption id="16" count="1" label="Hypertension - Subjects with comorbid conditions - Subjects with type 2 diabetes mellitus"/><FilterOption id="17732" count="1" label="Inflammatory bowel disease - Others - Healthy Subjects"/><FilterOption id="19591" count="1" label="Inflammatory bowel disease - Treatment Naive Subjects"/><FilterOption id="9802" count="1" label="Influenza virus infection - Subjects with Influenza - Subjects with acute influenza"/><FilterOption id="9804" count="1" label="Influenza virus infection - Subjects with Influenza - Subjects with seasonal influenza"/><FilterOption id="9806" count="1" label="Influenza virus infection - Subjects with Influenza - Subjects with uncomplicated influenza"/><FilterOption id="7610" count="1" label="Insulin dependent diabetes - Subjects with Diabetic Complications"/><FilterOption id="7646" count="1" label="Insulin dependent diabetes - Subjects with Good Glycemic Control"/><FilterOption id="7645" count="1" label="Insulin dependent diabetes - Subjects with Moderate Glycemic Control"/><FilterOption id="7644" count="1" label="Insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control"/><FilterOption id="7612" count="1" label="Insulin dependent diabetes - Subjects with diabetic macular edema"/><FilterOption id="11374" count="1" label="Interstitial lung disease - Subjects with History of/Scheduled for drug Therapy"/><FilterOption id="11375" count="1" label="Interstitial lung disease - Subjects with Treatment Resistant Disease"/><FilterOption id="3975" count="1" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="3979" count="1" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"/><FilterOption id="3977" count="1" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="3525" count="1" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"/><FilterOption id="3504" count="1" label="Lymphoma - Subjects with Specific Risk Stratified Lymphoma - Subjects with high risk"/><FilterOption id="3505" count="1" label="Lymphoma - Subjects with Specific Risk Stratified Lymphoma - Subjects with intermediate/high risk"/><FilterOption id="3506" count="1" label="Lymphoma - Subjects with Specific Risk Stratified Lymphoma - Subjects with low/intermediate risk"/><FilterOption id="3530" count="1" label="Lymphoma - Subjects with Treatment Resistant Disease"/><FilterOption id="18886" count="1" label="Macular edema - Subjects with Protocol Specified Vision Loss"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="48"><FilterOption count="3" label="201612"/><FilterOption count="3" label="201707"/><FilterOption count="3" label="201911"/><FilterOption count="2" label="200812"/><FilterOption count="2" label="201706"/><FilterOption count="2" label="201712"/><FilterOption count="2" label="201803"/><FilterOption count="2" label="202209"/><FilterOption count="1" label="200203"/><FilterOption count="1" label="200311"/><FilterOption count="1" label="200608"/><FilterOption count="1" label="200703"/><FilterOption count="1" label="200705"/><FilterOption count="1" label="200909"/><FilterOption count="1" label="201111"/><FilterOption count="1" label="201209"/><FilterOption count="1" label="201301"/><FilterOption count="1" label="201302"/><FilterOption count="1" label="201307"/><FilterOption count="1" label="201308"/><FilterOption count="1" label="201309"/><FilterOption count="1" label="201312"/><FilterOption count="1" label="201406"/><FilterOption count="1" label="201408"/><FilterOption count="1" label="201512"/><FilterOption count="1" label="201605"/><FilterOption count="1" label="201607"/><FilterOption count="1" label="201608"/><FilterOption count="1" label="201610"/><FilterOption count="1" label="201703"/><FilterOption count="1" label="201704"/><FilterOption count="1" label="201708"/><FilterOption count="1" label="201710"/><FilterOption count="1" label="201711"/><FilterOption count="1" label="201810"/><FilterOption count="1" label="201901"/><FilterOption count="1" label="201904"/><FilterOption count="1" label="201906"/><FilterOption count="1" label="201910"/><FilterOption count="1" label="201912"/><FilterOption count="1" label="202002"/><FilterOption count="1" label="202003"/><FilterOption count="1" label="202007"/><FilterOption count="1" label="202011"/><FilterOption count="1" label="202103"/><FilterOption count="1" label="202109"/><FilterOption count="1" label="202208"/><FilterOption count="1" label="202410"/></Filter><Filter label="Trial Country" name="trialCountries" total="64"><FilterOption id="ES" count="62" label="Spain"/><FilterOption id="DE" count="29" label="Germany"/><FilterOption id="FR" count="25" label="France"/><FilterOption id="IT" count="25" label="Italy"/><FilterOption id="GB" count="24" label="UK"/><FilterOption id="BE" count="18" label="Belgium"/><FilterOption id="AT" count="16" label="Austria"/><FilterOption id="NL" count="16" label="Netherlands"/><FilterOption id="PT" count="16" label="Portugal"/><FilterOption id="SE" count="16" label="Sweden"/><FilterOption id="US" count="16" label="US"/><FilterOption id="CA" count="15" label="Canada"/><FilterOption id="PL" count="14" label="Poland"/><FilterOption id="RU" count="14" label="Russian Federation"/><FilterOption id="KR" count="14" label="South Korea"/><FilterOption id="GR" count="13" label="Greece"/><FilterOption id="CH" count="13" label="Switzerland"/><FilterOption id="AU" count="12" label="Australia"/><FilterOption id="HU" count="12" label="Hungary"/><FilterOption id="CZ" count="11" label="Czech Republic"/><FilterOption id="IE" count="11" label="Ireland"/><FilterOption id="AR" count="10" label="Argentina"/><FilterOption id="ZA" count="10" label="South Africa"/><FilterOption id="TW" count="10" label="Taiwan"/><FilterOption id="HK" count="9" label="Hong Kong"/><FilterOption id="IL" count="9" label="Israel"/><FilterOption id="NZ" count="9" label="New Zealand"/><FilterOption id="NO" count="9" label="Norway"/><FilterOption id="BR" count="8" label="Brazil"/><FilterOption id="DK" count="8" label="Denmark"/><FilterOption id="MY" count="8" label="Malaysia"/><FilterOption id="MX" count="8" label="Mexico"/><FilterOption id="BG" count="7" label="Bulgaria"/><FilterOption id="JP" count="7" label="Japan"/><FilterOption id="SG" count="7" label="Singapore"/><FilterOption id="SK" count="7" label="Slovakia"/><FilterOption id="HR" count="6" label="Croatia"/><FilterOption id="FI" count="6" label="Finland"/><FilterOption id="RS" count="6" label="Serbia"/><FilterOption id="IN" count="5" label="India"/><FilterOption id="BY" count="4" label="Belarus"/><FilterOption id="GE" count="4" label="Georgia"/><FilterOption id="IS" count="4" label="Iceland"/><FilterOption id="LV" count="4" label="Latvia"/><FilterOption id="RO" count="4" label="Romania"/><FilterOption id="TH" count="4" label="Thailand"/><FilterOption id="TR" count="4" label="Turkey"/><FilterOption id="UA" count="4" label="Ukraine"/><FilterOption id="CL" count="3" label="Chile"/><FilterOption id="CN" count="3" label="China"/><FilterOption id="LT" count="3" label="Lithuania"/><FilterOption id="LK" count="3" label="Sri Lanka"/><FilterOption id="X2" count="2" label="Asia"/><FilterOption id="CO" count="2" label="Colombia"/><FilterOption id="X5" count="2" label="Europe"/><FilterOption id="PA" count="2" label="Panama"/><FilterOption id="PH" count="2" label="Philippines"/><FilterOption id="XF" count="1" label="Central America"/><FilterOption id="EC" count="1" label="Ecuador"/><FilterOption id="JO" count="1" label="Jordan"/><FilterOption id="MA" count="1" label="Morocco"/><FilterOption id="PE" count="1" label="Peru"/><FilterOption id="PR" count="1" label="Puerto Rico"/><FilterOption id="SI" count="1" label="Slovenia"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="14"><FilterOption id="EAAAD" count="62" label="Aged Adults (65-79 yrs)"/><FilterOption id="EAMAA" count="59" label="Middle-aged Adults (45-64 yrs)"/><FilterOption id="EAYAD" count="59" label="Young Adults (18-44 yrs)"/><FilterOption id="EAELD" count="51" label="Elderly Adults (80 and over)"/><FilterOption id="EVHVA" count="3" label="Healthy volunteers accepted"/><FilterOption id="EAADL" count="2" label="Adolescents (13-17 yrs)"/><FilterOption id="EGMAL" count="2" label="Male"/><FilterOption id="ECASI" count="1" label="Asian Ancestry"/><FilterOption id="EACHI" count="1" label="Children (6-12 yrs)"/><FilterOption id="ECEUR" count="1" label="European Ancestry"/><FilterOption id="EAINF" count="1" label="Infants (6-23 months)"/><FilterOption id="ECJAP" count="1" label="Japanese Ancestry"/><FilterOption id="EANEW" count="1" label="Newborn Infants (up to 5 months)"/><FilterOption id="EAPRE" count="1" label="Preschool Children (2-5 yrs)"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="20"><FilterOption id="SSTINV" count="49" label="Interventional"/><FilterOption id="SIPTRE" count="44" label="Treatment"/><FilterOption id="SISPRL" count="37" label="Parallel Assignment"/><FilterOption id="SIARND" count="35" label="Randomized"/><FilterOption id="SIMOPN" count="25" label="Open Label"/><FilterOption id="SIMMBD" count="20" label="Multiple Blind"/><FilterOption id="SICPLC" count="17" label="Placebo Control"/><FilterOption id="SSTOBS" count="14" label="Observational"/><FilterOption id="SICACT" count="12" label="Active Control"/><FilterOption id="SIANON" count="11" label="Non-Randomized"/><FilterOption id="SOTPRO" count="11" label="Prospective"/><FilterOption id="SISSNG" count="11" label="Single Group Assignment"/><FilterOption id="SOSCOH" count="10" label="Cohort"/><FilterOption id="SICNOC" count="6" label="No Control"/><FilterOption id="SIPPRE" count="4" label="Prevention"/><FilterOption id="SIMSBD" count="4" label="Single Blind"/><FilterOption id="SODXSC" count="2" label="Cross-sectional"/><FilterOption id="SISXOV" count="1" label="Crossover Assignment"/><FilterOption id="SIPDIA" count="1" label="Diagnosis"/><FilterOption id="SODLNG" count="1" label="Longitudinal"/></Filter><Filter label="Trial Source" name="trialSources" total="2"><FilterOption id="CTGOV" count="40" label="ClinicalTrials.gov only"/><FilterOption id="CTGOVOTHERS" count="23" label="ClinicalTrials.gov and others"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="44"><FilterOption id="2953" count="22" label="Anti-inflammatory"/><FilterOption id="1545" count="13" label="Anticancer"/><FilterOption id="61" count="10" label="Angiogenesis inhibitor"/><FilterOption id="2657" count="8" label="Antihypertensive"/><FilterOption id="62255" count="6" label="Anticancer protein kinase inhibitor"/><FilterOption id="2946" count="5" label="Analgesic"/><FilterOption id="55685" count="5" label="Anticancer monoclonal antibody"/><FilterOption id="1594" count="4" label="Antibacterial"/><FilterOption id="1589" count="4" label="Apoptosis stimulator"/><FilterOption id="664" count="3" label="Fibrosuppressant"/><FilterOption id="396" count="3" label="Immunosuppressant"/><FilterOption id="312" count="3" label="Platelet aggregation inhibitor"/><FilterOption id="15184" count="3" label="Systemic antipsoriatic product"/><FilterOption id="449" count="2" label="Antiarrhythmic agent"/><FilterOption id="991" count="2" label="Antiviral"/><FilterOption id="137" count="2" label="Diuretic agent"/><FilterOption id="610" count="2" label="Hematopoietic stimulator"/><FilterOption id="399" count="2" label="Hypoglycemic agent"/><FilterOption id="1596" count="2" label="Immunomodulator"/><FilterOption id="382" count="2" label="TNF alpha synthesis inhibitor"/><FilterOption id="882" count="1" label="5-HETE modulator"/><FilterOption id="50" count="1" label="Anticancer alkylating agent"/><FilterOption id="2941" count="1" label="Antidepressant"/><FilterOption id="74" count="1" label="Antioxidant agent"/><FilterOption id="3984" count="1" label="Bacterial nucleic acid synthesis inhibitor"/><FilterOption id="89" count="1" label="Bone resorption inhibitor"/><FilterOption id="646" count="1" label="Bronchodilator"/><FilterOption id="2659" count="1" label="Cardioprotectant"/><FilterOption id="5579" count="1" label="Chemotaxis modulator"/><FilterOption id="3189" count="1" label="Corticosteroid agonist"/><FilterOption id="750" count="1" label="DNA intercalator"/><FilterOption id="5630" count="1" label="Eosinophil migration modulator"/><FilterOption id="1332" count="1" label="Gastrointestinal system agent"/><FilterOption id="450" count="1" label="Neuromuscular blocking agent"/><FilterOption id="15148" count="1" label="Ocular antineovascularisation agent"/><FilterOption id="12592" count="1" label="Osteoblast modulator"/><FilterOption id="472" count="1" label="Phosphate lowering agent"/><FilterOption id="1467" count="1" label="Renal system agent"/><FilterOption id="2954" count="1" label="Steroidal anti-inflammatory"/><FilterOption id="7293" count="1" label="Synergist"/><FilterOption id="15187" count="1" label="Systemic dermatological antibacterial product"/><FilterOption id="15180" count="1" label="Topical antipruritic product"/><FilterOption id="388" count="1" label="Vasodilator"/><FilterOption id="2593" count="1" label="Vitamin D analog"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="2"><FilterOption id="UNSPECIFIED" count="13" label="Unspecified"/><FilterOption id="YES" count="2" label="Yes"/></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="15907" count="6" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="2622" count="4" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="2704" count="4" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)"/><FilterOption id="6407" count="4" label="Crohns disease - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="2623" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"/><FilterOption id="7538" count="3" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="15971" count="3" label="Ulcerative colitis - Protocol Specified Other Endpoints"/><FilterOption id="17273" count="2" label="Anemia - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="2492" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="2619" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"/><FilterOption id="2654" count="2" label="Coronary artery disease - Assessment of Hemorrhagic Complications - Major/minor bleeding"/><FilterOption id="2518" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis (Definite /Probable /Possible)"/><FilterOption id="2565" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis"/><FilterOption id="2703" count="2" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="6406" count="2" label="Crohns disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="6339" count="2" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"/><FilterOption id="11329" count="2" label="Diabetic complication - Assessment of Adverse Events"/><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"/><FilterOption id="22596" count="2" label="End stage renal disease - Assessment of Mortality/Death Rates"/><FilterOption id="22595" count="2" label="End stage renal disease - Assessment of adverse events"/><FilterOption id="44" count="2" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Trough DBP"/><FilterOption id="115" count="2" label="Hypertension - Assessment of Electrocardiography (ECG) Findings"/><FilterOption id="261" count="2" label="Hypertension - Assessment of Safety and Tolerability"/><FilterOption id="25" count="2" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP"/><FilterOption id="29" count="2" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Trough SBP"/><FilterOption id="8077" count="2" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="7544" count="2" label="Lymphoma - Assessment of Disease Free Survival (DFS)"/><FilterOption id="7611" count="2" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="7558" count="2" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7680" count="2" label="Lymphoma - Assessment of adverse events"/><FilterOption id="7488" count="2" label="Multiple myeloma - Assessment of Safety and Tolerability"/><FilterOption id="15881" count="2" label="Ulcerative colitis - Assessment of Clinical Response"/><FilterOption id="15896" count="2" label="Ulcerative colitis - Assessment of Disease Relapse/Recurrence - Assessment of time to relapse"/><FilterOption id="16721" count="2" label="Ulcerative colitis - Assessment of Inflammatory &amp; Oxidative Stress Markers"/><FilterOption id="15950" count="2" label="Ulcerative colitis - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="15967" count="2" label="Ulcerative colitis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="15890" count="2" label="Ulcerative colitis - Assessment of Remission - Assessment of steroid-free remission"/><FilterOption id="15934" count="2" label="Ulcerative colitis - Assessment of use of Rescue Medication - Assessment by steroid/immunosuppressant use"/><FilterOption id="2940" count="1" label="Acute coronary syndrome - Assessment of Therapy Related Outcomes - Efficacy parameters"/><FilterOption id="2941" count="1" label="Acute coronary syndrome - Assessment of Therapy Related Outcomes - Safety parameters"/><FilterOption id="17257" count="1" label="Anemia - Assessment of Cardiac Function"/><FilterOption id="17267" count="1" label="Anemia - Assessment of Co-morbidity - Assessment of cardiac diseases/disorders"/><FilterOption id="17363" count="1" label="Anemia - Assessment of Mortality/Death Rates"/><FilterOption id="17357" count="1" label="Anemia - Assessment of Safety and Tolerability - Assessment of serious adverse events"/><FilterOption id="17324" count="1" label="Anemia - Assessment of Therapy Related Outcomes - Assessment of efficacy"/><FilterOption id="17321" count="1" label="Anemia - Assessment of Therapy Related Outcomes - Assessment of treatment utilization/alterations"/><FilterOption id="17255" count="1" label="Anemia - Assessment of Vital Signs"/><FilterOption id="17356" count="1" label="Anemia - Assessment of adverse events"/><FilterOption id="17253" count="1" label="Anemia - Clinical Assessments"/><FilterOption id="17294" count="1" label="Anemia - Hematological Assessments - Assessment of hemoglobin response"/><FilterOption id="17220" count="1" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"/><FilterOption id="6081" count="1" label="Asthma - Assessment of Clinical Response - Assessment of time to treatment failure (TTF)"/><FilterOption id="5985" count="1" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"/><FilterOption id="5987" count="1" label="Asthma - Assessment of Exacerbations - Time to first exacerbation"/><FilterOption id="5944" count="1" label="Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1"/><FilterOption id="6005" count="1" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide"/><FilterOption id="6000" count="1" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Blood eosinophils"/><FilterOption id="6009" count="1" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum immunoglobulins"/><FilterOption id="37469" count="1" label="Asthma - Health Economic Assessments - Health Services Utilization"/><FilterOption id="6111" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)"/><FilterOption id="27645" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control test (ACT)"/><FilterOption id="26737" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Mini asthma quality of life questionnaire (MiniAQLQ)"/><FilterOption id="9492" count="1" label="Atrial fibrillation - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction"/><FilterOption id="9504" count="1" label="Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of ischemic stroke"/><FilterOption id="9509" count="1" label="Atrial fibrillation - Assessment of Hemorrhagic Complications"/><FilterOption id="9439" count="1" label="Atrial fibrillation - Assessment of Mortality/Death Rates - Assessment of cardiovascular death"/><FilterOption id="9645" count="1" label="Atrial fibrillation - Assessment of Safety and Tolerability"/><FilterOption id="9630" count="1" label="Atrial fibrillation - Assessment of Therapy Related Outcomes"/><FilterOption id="9520" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of stent thrombosis"/><FilterOption id="9516" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events"/><FilterOption id="9646" count="1" label="Atrial fibrillation - Assessment of adverse events"/><FilterOption id="45399" count="1" label="Atrial fibrillation - Imaging/Radiological Assessments"/><FilterOption id="9666" count="1" label="Atrial fibrillation - Protocol Specified Other Endpoints"/><FilterOption id="1029" count="1" label="Cardiac failure - Assessment of Cardiovascular Events - Cardiovascular intervention/surgery"/><FilterOption id="587" count="1" label="Cardiac failure - Assessment of Clinical Symptoms - Assessment of arrhythmia"/><FilterOption id="963" count="1" label="Cardiac failure - Assessment of Liver Functions"/><FilterOption id="558" count="1" label="Cardiac failure - Assessment of Non Cardiovascular Events - Assessment of cerebrovascular adverse events (Stroke/TIA)"/><FilterOption id="45425" count="1" label="Cardiac failure - Assessment of Renal Dysfunction/Events"/><FilterOption id="1321" count="1" label="Cardiac failure - Assessment of Safety and Tolerability"/><FilterOption id="557" count="1" label="Cardiac failure - Assessment of adverse events"/><FilterOption id="844" count="1" label="Cardiac failure - Assessment of hospitalization - Assessment of rehospitalizations"/><FilterOption id="609" count="1" label="Cardiac failure - Hematological Assessments"/><FilterOption id="1085" count="1" label="Cardiac failure - Protocol Specified Other Endpoints - Laboratory assessment - unspecified parameters"/><FilterOption id="1138" count="1" label="Cardiac failure - Protocol Specified Other Endpoints - Resuscitated cardiac arrest"/><FilterOption id="1103" count="1" label="Cardiac failure - Requirement of Ventilatory Support/Intervention - Assessment of requirement of mechanical ventilation"/><FilterOption id="4566" count="1" label="Chronic obstructive pulmonary disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"/><FilterOption id="4468" count="1" label="Chronic obstructive pulmonary disease - Assessment of hospitalization - Readmission/time to readmission"/><FilterOption id="29218" count="1" label="Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)"/><FilterOption id="2664" count="1" label="Coronary artery disease - Assessment of Artery Plaque /Atheroma - Vessel Lumen Patency/Change in lumen area and volume"/><FilterOption id="2491" count="1" label="Coronary artery disease - Assessment of Cardiovascular Events"/><FilterOption id="2621" count="1" label="Coronary artery disease - Assessment of Mortality/Death Rates"/><FilterOption id="2667" count="1" label="Coronary artery disease - Assessment of Procedure and Procedure Related Events - Coronary Angiography"/><FilterOption id="2686" count="1" label="Coronary artery disease - Assessment of Procedure and Procedure Related Events - Procedural success"/><FilterOption id="2689" count="1" label="Coronary artery disease - Assessment of Reperfusion/Revascularization"/><FilterOption id="2551" count="1" label="Coronary artery disease - Assessment of Stenosis/Restenosis - In-segment late loss/In-lesion late loss"/><FilterOption id="2542" count="1" label="Coronary artery disease - Assessment of Stenosis/Restenosis"/><FilterOption id="2749" count="1" label="Coronary artery disease - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment"/><FilterOption id="2754" count="1" label="Coronary artery disease - Assessment of Therapy Related Outcomes - Safety assessment"/><FilterOption id="2593" count="1" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Vascular complications"/><FilterOption id="2774" count="1" label="Coronary artery disease - Assessment of hospitalization"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="2586" count="5" label="Blood pressure"/><FilterOption id="1904" count="5" label="Heart rate"/><FilterOption id="44216" count="4" label="Body temperature"/><FilterOption id="1236" count="4" label="Hemoglobin"/><FilterOption id="173" count="4" label="Matrix metalloproteinase-9"/><FilterOption id="10260" count="4" label="Respiratory frequency"/><FilterOption id="46" count="3" label="C-reactive protein"/><FilterOption id="3098" count="3" label="Calprotectin"/><FilterOption id="248" count="3" label="Eosinophils"/><FilterOption id="2713" count="3" label="Forced expiratory volume"/><FilterOption id="557" count="3" label="Lactotransferrin"/><FilterOption id="10169" count="3" label="Oxygen saturation"/><FilterOption id="12058" count="3" label="Total body mass"/><FilterOption id="118" count="2" label="Albumin"/><FilterOption id="28899" count="2" label="Alkaline phosphatase"/><FilterOption id="1731" count="2" label="B-lymphocyte antigen CD20"/><FilterOption id="4529" count="2" label="Bicarbonates"/><FilterOption id="2417" count="2" label="Calcium"/><FilterOption id="3247" count="2" label="Chlorides"/><FilterOption id="8024" count="2" label="Creatine kinase"/><FilterOption id="213" count="2" label="Creatinine"/><FilterOption id="332" count="2" label="Diastolic blood pressure"/><FilterOption id="1912" count="2" label="Forced Vital Capacity"/><FilterOption id="30834" count="2" label="Fractional concentration of exhaled nitric oxide"/><FilterOption id="1221" count="2" label="Hematocrit"/><FilterOption id="4806" count="2" label="Lymphocytes"/><FilterOption id="105" count="2" label="Natriuretic peptides B"/><FilterOption id="3083" count="2" label="Phosphate"/><FilterOption id="2382" count="2" label="Phosphorus"/><FilterOption id="38" count="2" label="Prostate-specific antigen"/><FilterOption id="7659" count="2" label="Q-wave"/><FilterOption id="147" count="2" label="Six-minute walk distance"/><FilterOption id="2662" count="2" label="Sodium"/><FilterOption id="330" count="2" label="Systolic blood pressure"/><FilterOption id="33513" count="2" label="Troponin"/><FilterOption id="2358" count="2" label="Urea nitrogen"/><FilterOption id="286" count="1" label="72 kDa type IV collagenase"/><FilterOption id="45837" count="1" label="A disintegrin and metalloproteinase with thrombospondin motifs"/><FilterOption id="2645" count="1" label="Activated Clotting Time"/><FilterOption id="1211" count="1" label="Alanine transaminase"/><FilterOption id="450" count="1" label="Alkaline phosphatase, tissue-nonspecific isozyme"/><FilterOption id="7051" count="1" label="Anti-erythropoietin antibodies"/><FilterOption id="2527" count="1" label="Aspartate aminotransferase"/><FilterOption id="6663" count="1" label="B-lymphocytes"/><FilterOption id="9807" count="1" label="Basophils"/><FilterOption id="165" count="1" label="Beta-2-microglobulin"/><FilterOption id="2387" count="1" label="Bilirubin"/><FilterOption id="2054" count="1" label="Blood platelets"/><FilterOption id="17697" count="1" label="Body height"/><FilterOption id="113" count="1" label="Body Mass Index"/><FilterOption id="20660" count="1" label="Bone formation rate"/><FilterOption id="3374" count="1" label="Bone mineral density"/><FilterOption id="6192" count="1" label="Calcifediol"/><FilterOption id="1906" count="1" label="Carbon monoxide diffusing capacity"/><FilterOption id="9591" count="1" label="Collagen type I"/><FilterOption id="9592" count="1" label="Collagen type III"/><FilterOption id="21584" count="1" label="Colon"/><FilterOption id="8372" count="1" label="Coronary flow reserve"/><FilterOption id="181" count="1" label="Creatine Kinase, MB Form"/><FilterOption id="1314" count="1" label="Cytochrome b-245 light chain"/><FilterOption id="1629" count="1" label="Endoribonuclease Dicer"/><FilterOption id="4522" count="1" label="Erythrocytes"/><FilterOption id="394" count="1" label="Erythropoietin"/><FilterOption id="7895" count="1" label="Estimated glomerular filtration rate"/><FilterOption id="19377" count="1" label="Fraction of inspired oxygen"/><FilterOption id="10487" count="1" label="Fractional Flow Reserve"/><FilterOption id="1735" count="1" label="Glucose"/><FilterOption id="1937" count="1" label="Immunoglobulin E"/><FilterOption id="30226" count="1" label="Immunoglobulins"/><FilterOption id="176" count="1" label="Interleukin-6"/><FilterOption id="29618" count="1" label="International Normalized Ratio"/><FilterOption id="402" count="1" label="Interstitial collagenase"/><FilterOption id="1239" count="1" label="Iron"/><FilterOption id="30214" count="1" label="Joint swelling"/><FilterOption id="30217" count="1" label="Joint tenderness"/><FilterOption id="154" count="1" label="Lactate dehydrogenase"/><FilterOption id="125" count="1" label="Leukocyte count"/><FilterOption id="152" count="1" label="Low-density lipoprotein cholesterol"/><FilterOption id="2515" count="1" label="Magnesium"/><FilterOption id="1381" count="1" label="Matrix metalloproteinase-13"/><FilterOption id="1296" count="1" label="Mean corpuscular volume"/><FilterOption id="26184" count="1" label="Microcirculatory resistance index"/><FilterOption id="653" count="1" label="MMP-2-TIMP-2 complex"/><FilterOption id="8097" count="1" label="Monocytes"/><FilterOption id="19714" count="1" label="Muscle strength"/><FilterOption id="10833" count="1" label="Myomesin-2"/><FilterOption id="2521" count="1" label="NADPH oxidase"/><FilterOption id="933" count="1" label="Neutrophil collagenase"/><FilterOption id="4520" count="1" label="Neutrophil cytosol factor 4"/><FilterOption id="1925" count="1" label="Neutrophils"/><FilterOption id="439" count="1" label="Parathyroid hormone"/><FilterOption id="2699" count="1" label="Partial pressure of carbon dioxide"/><FilterOption id="2689" count="1" label="Partial pressure of oxygen"/><FilterOption id="3934" count="1" label="Periostin"/><FilterOption id="2098" count="1" label="Potassium"/><FilterOption id="10909" count="1" label="Pulmonary artery systolic pressure"/><FilterOption id="3183" count="1" label="Ras-related C3 botulinum toxin substrate 2"/><FilterOption id="3054" count="1" label="Reticulocytes"/><FilterOption id="11304" count="1" label="Retina"/><FilterOption id="9750" count="1" label="Right ventricle"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="4"><FilterOption id="SIEEFC" count="48" label="Efficacy"/><FilterOption id="SIESFT" count="46" label="Safety"/><FilterOption id="SIEPCK" count="8" label="Pharmacokinetics"/><FilterOption id="SIEPCD" count="6" label="Pharmacodynamics"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="10"><FilterOption id="6736" count="3" label="rituximab"/><FilterOption id="15954" count="2" label="bortezomib"/><FilterOption id="2836" count="2" label="clopidogrel"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="47000" count="1" label="bendamustine"/><FilterOption id="8047" count="1" label="bevacizumab"/><FilterOption id="24343" count="1" label="dabigatran etexilate"/><FilterOption id="3159" count="1" label="fluticasone propionate"/><FilterOption id="11519" count="1" label="mitoxantrone"/><FilterOption id="36332" count="1" label="ticagrelor"/></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="PR" count="12" label="Press Releases"/><FilterOption id="SERIAL" count="12" label="Serial Publications"/><FilterOption id="OTHER" count="9" label="Other Publications"/><FilterOption id="CORPORATE" count="5" label="Corporate Publications"/><FilterOption id="CONFERENCE" count="2" label="Conference Reports"/></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="34"><FilterOption id="67629" count="4" label="filgotinib"/><FilterOption id="51160" count="3" label="nintedanib"/><FilterOption id="12151" count="2" label="atrasentan"/><FilterOption id="29831" count="2" label="sorafenib"/><FilterOption id="70337" count="2" label="telmisartan + hydrochlorothiazide"/><FilterOption id="5051" count="2" label="telmisartan"/><FilterOption id="61574" count="2" label="umirolimus stent (BioMatrix, restenosis), Biosensors"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="44897" count="1" label="apremilast"/><FilterOption id="54263" count="1" label="bardoxolone methyl (oral, pulmonary arterial hypertension/ diabetic nephropathy), Reata/ Kyowa Hakko Kirin"/><FilterOption id="39893" count="1" label="capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal"/><FilterOption id="8715" count="1" label="eletriptan"/><FilterOption id="87805" count="1" label="faricimab"/><FilterOption id="91352" count="1" label="fulacimstat"/><FilterOption id="42857" count="1" label="golimumab"/><FilterOption id="6850" count="1" label="infliximab"/><FilterOption id="78759" count="1" label="infliximab biosimilar, Celltrion/Nippon Kayaku/Hospira/Orion/EGIS Gyogyszergyar"/><FilterOption id="35644" count="1" label="methoxy polyethylene glycol-epoetin beta"/><FilterOption id="3648" count="1" label="molgramostim"/><FilterOption id="12978" count="1" label="moxifloxacin"/><FilterOption id="9000" count="1" label="onabotulinumtoxinA"/><FilterOption id="45817" count="1" label="paricalcitol (oral), Abbott"/><FilterOption id="43738" count="1" label="pazopanib"/><FilterOption id="5968" count="1" label="reslizumab"/><FilterOption id="86582" count="1" label="RG-7745"/><FilterOption id="6736" count="1" label="rituximab"/><FilterOption id="49398" count="1" label="sevelamer carbonate (tablet, renal disease/hyperphosphatemia), Genzyme"/><FilterOption id="8713" count="1" label="sildenafil citrate"/><FilterOption id="54730" count="1" label="sotatercept"/><FilterOption id="12973" count="1" label="sunitinib"/><FilterOption id="36332" count="1" label="ticagrelor"/><FilterOption id="6259" count="1" label="tocilizumab (intravenous), Roche/Chugai"/><FilterOption id="42858" count="1" label="ustekinumab"/><FilterOption id="12406" count="1" label="vedolizumab"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="7"><FilterOption id="15954" count="1" label="bortezomib"/><FilterOption id="2836" count="1" label="clopidogrel"/><FilterOption id="7413" count="1" label="darbepoetin alfa"/><FilterOption id="8121" count="1" label="epoetin beta, Roche"/><FilterOption id="8050" count="1" label="thalidomide, Celgene"/><FilterOption id="36332" count="1" label="ticagrelor"/><FilterOption id="44375" count="1" label="warfarin"/></Filter><Filter label="Trial Category" name="trialCategory" total="7"><FilterOption id="4" count="42" label="Small molecule"/><FilterOption id="3" count="15" label="Biological"/><FilterOption id="8" count="15" label="Medical device"/><FilterOption id="9" count="4" label="Medical procedure"/><FilterOption id="16" count="2" label="Behavioral intervention"/><FilterOption id="18" count="2" label="Pathophysiology"/><FilterOption id="17" count="1" label="Biomarker identification"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="NO" count="48" label="No"/><FilterOption id="YES" count="15" label="Yes"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="70"><FilterOption id="3806" count="5" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="948" count="5" label="PDGF receptor antagonist"/><FilterOption id="48492" count="5" label="PDGF receptor beta antagonist"/><FilterOption id="1722" count="5" label="VEGF receptor antagonist"/><FilterOption id="3846" count="5" label="VEGF-1 receptor antagonist"/><FilterOption id="3848" count="5" label="VEGF-2 receptor antagonist"/><FilterOption id="3850" count="5" label="VEGF-3 receptor antagonist"/><FilterOption id="3154" count="4" label="CSF-1 antagonist"/><FilterOption id="3682" count="4" label="FGF1 receptor antagonist"/><FilterOption id="3688" count="4" label="FGF3 receptor antagonist"/><FilterOption id="3562" count="4" label="Jak1 tyrosine kinase inhibitor"/><FilterOption id="3584" count="4" label="Lck tyrosine kinase inhibitor"/><FilterOption id="48489" count="4" label="PDGF receptor alpha antagonist"/><FilterOption id="64" count="3" label="Angiotensin II receptor antagonist"/><FilterOption id="5085" count="3" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="168" count="3" label="FGF receptor antagonist"/><FilterOption id="3685" count="3" label="FGF2 receptor antagonist"/><FilterOption id="3586" count="3" label="Lyn tyrosine kinase inhibitor"/><FilterOption id="4913" count="3" label="P2Y12 purinoceptor antagonist"/><FilterOption id="3576" count="3" label="Src tyrosine kinase inhibitor"/><FilterOption id="76469" count="2" label="26S proteasome complex inhibitor"/><FilterOption id="770" count="2" label="Endothelin ET-A receptor antagonist"/><FilterOption id="3808" count="2" label="Kit tyrosine kinase inhibitor"/><FilterOption id="10240" count="2" label="mTOR inhibitor"/><FilterOption id="4917" count="2" label="Proteasome inhibitor"/><FilterOption id="4550" count="2" label="Raf 1 protein kinase inhibitor"/><FilterOption id="4548" count="2" label="Raf B protein kinase inhibitor"/><FilterOption id="4542" count="2" label="Raf protein kinase inhibitor"/><FilterOption id="3816" count="2" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="381" count="2" label="TNF alpha ligand inhibitor"/><FilterOption id="721" count="2" label="TNF binding agent"/><FilterOption id="8" count="1" label="5-HT 1b receptor agonist"/><FilterOption id="10" count="1" label="5-HT 1d receptor agonist"/><FilterOption id="162" count="1" label="Acetylcholine receptor antagonist"/><FilterOption id="4578" count="1" label="Activin type-II receptor antagonist"/><FilterOption id="14323" count="1" label="Angiopoietin ligand-2 inhibitor"/><FilterOption id="6876" count="1" label="Bone morphogenetic protein-11 ligand inhibitor"/><FilterOption id="1744" count="1" label="Chymase inhibitor"/><FilterOption id="420" count="1" label="CSF-1 agonist"/><FilterOption id="431" count="1" label="DNA gyrase inhibitor"/><FilterOption id="2501" count="1" label="Erythropoietin receptor agonist"/><FilterOption id="111" count="1" label="Factor IIa antagonist"/><FilterOption id="410" count="1" label="GM-CSF receptor agonist"/><FilterOption id="52120" count="1" label="Hemagglutinin modulator"/><FilterOption id="4476" count="1" label="I-kappa B kinase inhibitor"/><FilterOption id="1584" count="1" label="IL-12 receptor antagonist"/><FilterOption id="9748" count="1" label="IL-23 antagonist"/><FilterOption id="226" count="1" label="IL-5 receptor antagonist"/><FilterOption id="471" count="1" label="IL-6 receptor antagonist"/><FilterOption id="3058" count="1" label="IL-6 receptor modulator"/><FilterOption id="2950" count="1" label="Integrin alpha-4/beta-7 antagonist"/><FilterOption id="12491" count="1" label="Interleukin-5 ligand inhibitor"/><FilterOption id="3594" count="1" label="Itk tyrosine kinase inhibitor"/><FilterOption id="48829" count="1" label="Kelch like ECH associated protein 1 modulator"/><FilterOption id="3738" count="1" label="Ltk tyrosine kinase receptor inhibitor"/><FilterOption id="2617" count="1" label="MAdCAM inhibitor"/><FilterOption id="19519" count="1" label="NFE2L2 gene stimulator"/><FilterOption id="2653" count="1" label="Nuclear factor kappa B inhibitor"/><FilterOption id="55100" count="1" label="p130Cas associated protein inhibitor"/><FilterOption id="2506" count="1" label="PARP modulator"/><FilterOption id="304" count="1" label="PDE 4 inhibitor"/><FilterOption id="778" count="1" label="PDE 5 inhibitor"/><FilterOption id="11192" count="1" label="Protease-activated receptor-1 antagonist"/><FilterOption id="385" count="1" label="Protein tyrosine kinase inhibitor"/><FilterOption id="19075" count="1" label="STAT3 gene inhibitor"/><FilterOption id="1513" count="1" label="Topoisomerase II modulator"/><FilterOption id="9320" count="1" label="Topoisomerase IV inhibitor"/><FilterOption id="6937" count="1" label="Vanilloid VR1 agonist"/><FilterOption id="12521" count="1" label="VEGF ligand inhibitor"/><FilterOption id="1689" count="1" label="VEGF-A ligand inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="41"><FilterOption id="27741" count="4" label="Galapagos NV"/><FilterOption id="19446" count="3" label="Roche Holding AG"/><FilterOption id="1069026" count="2" label="Effice Servicios Para la Investigacion"/><FilterOption id="1017818" count="2" label="Instituto de Salud Carlos III"/><FilterOption id="13626" count="1" label="Abbott Laboratories Ltd"/><FilterOption id="1061163" count="1" label="Abbott Vascular"/><FilterOption id="1066960" count="1" label="Adverum Biotechnologies Inc"/><FilterOption id="14109" count="1" label="Amgen Inc"/><FilterOption id="1012397" count="1" label="Arisaph Pharmaceuticals Inc"/><FilterOption id="31524" count="1" label="Asahi Intecc Co Ltd"/><FilterOption id="1013295" count="1" label="Astellas Pharma Inc"/><FilterOption id="1158336" count="1" label="AstraZeneca AB, spain"/><FilterOption id="14190" count="1" label="AstraZeneca plc"/><FilterOption id="14438" count="1" label="Baxter Healthcare Corp"/><FilterOption id="1016827" count="1" label="Biosensors International Group Ltd"/><FilterOption id="15065" count="1" label="Bristol-Myers Squibb Co"/><FilterOption id="1017506" count="1" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1053612" count="1" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="19453" count="1" label="Genentech Inc"/><FilterOption id="1010293" count="1" label="Hospira Inc"/><FilterOption id="1131033" count="1" label="Hospital Costa del Sol"/><FilterOption id="1164375" count="1" label="Hospital de Antequera"/><FilterOption id="1059304" count="1" label="Hospital de Basurto"/><FilterOption id="1080926" count="1" label="Hospital de Sabadell"/><FilterOption id="1164374" count="1" label="Hospital Santa Marina"/><FilterOption id="1040940" count="1" label="Hospital Universitari de Bellvitge"/><FilterOption id="1051496" count="1" label="Hospital Universitario Donostia"/><FilterOption id="1044505" count="1" label="Hospital Universitario de Canarias"/><FilterOption id="1058215" count="1" label="Hospital Universitario de La Princesa"/><FilterOption id="1168890" count="1" label="Instituto de Investigación Biomédica de Salamanca"/><FilterOption id="1119275" count="1" label="Instituto de Investigación Sanitaria Hospital Universitario de La Princesa"/><FilterOption id="17332" count="1" label="Johnson &amp; Johnson"/><FilterOption id="18077" count="1" label="Merck &amp; Co Inc"/><FilterOption id="1054113" count="1" label="National Health Service"/><FilterOption id="1099505" count="1" label="Osakidetza"/><FilterOption id="1077534" count="1" label="Sociedad Española de Neumología y Cirugía Torácica"/><FilterOption id="28185" count="1" label="St Jude Medical Inc"/><FilterOption id="20300" count="1" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="20341" count="1" label="Terumo Corp"/><FilterOption id="29076" count="1" label="Teva Pharmaceuticals USA Inc"/><FilterOption id="1114403" count="1" label="TFS Trial Form Support"/></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="16"><FilterOption id="1545" count="4" label="Anticancer"/><FilterOption id="61" count="2" label="Angiogenesis inhibitor"/><FilterOption id="2953" count="2" label="Anti-inflammatory"/><FilterOption id="312" count="2" label="Platelet aggregation inhibitor"/><FilterOption id="2946" count="1" label="Analgesic"/><FilterOption id="1594" count="1" label="Antibacterial"/><FilterOption id="55685" count="1" label="Anticancer monoclonal antibody"/><FilterOption id="2657" count="1" label="Antihypertensive"/><FilterOption id="991" count="1" label="Antiviral"/><FilterOption id="1589" count="1" label="Apoptosis stimulator"/><FilterOption id="659" count="1" label="Coagulation inhibitor"/><FilterOption id="610" count="1" label="Hematopoietic stimulator"/><FilterOption id="1596" count="1" label="Immunomodulator"/><FilterOption id="15148" count="1" label="Ocular antineovascularisation agent"/><FilterOption id="15184" count="1" label="Systemic antipsoriatic product"/><FilterOption id="382" count="1" label="TNF alpha synthesis inhibitor"/></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="22" label="Proteomic"/><FilterOption id="38" count="21" label="Genomic"/><FilterOption id="31" count="21" label="Physiological"/><FilterOption id="32" count="9" label="Biochemical"/><FilterOption id="40" count="7" label="Structural (imaging)"/><FilterOption id="75" count="6" label="Cellular"/><FilterOption id="39" count="3" label="Anthropomorphic"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="31" label="Therapeutic effect marker"/><FilterOption id="730490367" count="9" label="Toxic effect marker"/><FilterOption id="1571666123" count="6" label="Disease marker"/><FilterOption id="3242045531" count="2" label="Not determined"/></Filter><Filter label="Interventions" name="trialInterventions" total="42"><FilterOption id="67629" count="4" label="filgotinib"/><FilterOption id="51160" count="3" label="nintedanib"/><FilterOption id="6736" count="3" label="rituximab"/><FilterOption id="12151" count="2" label="atrasentan"/><FilterOption id="15954" count="2" label="bortezomib"/><FilterOption id="2836" count="2" label="clopidogrel"/><FilterOption id="29831" count="2" label="sorafenib"/><FilterOption id="70337" count="2" label="telmisartan + hydrochlorothiazide"/><FilterOption id="5051" count="2" label="telmisartan"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="36332" count="2" label="ticagrelor"/><FilterOption id="61574" count="2" label="umirolimus stent (BioMatrix, restenosis), Biosensors"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="44897" count="1" label="apremilast"/><FilterOption id="54263" count="1" label="bardoxolone methyl (oral, pulmonary arterial hypertension/ diabetic nephropathy), Reata/ Kyowa Hakko Kirin"/><FilterOption id="47000" count="1" label="bendamustine"/><FilterOption id="8047" count="1" label="bevacizumab"/><FilterOption id="39893" count="1" label="capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal"/><FilterOption id="24343" count="1" label="dabigatran etexilate"/><FilterOption id="8715" count="1" label="eletriptan"/><FilterOption id="87805" count="1" label="faricimab"/><FilterOption id="3159" count="1" label="fluticasone propionate"/><FilterOption id="91352" count="1" label="fulacimstat"/><FilterOption id="42857" count="1" label="golimumab"/><FilterOption id="6850" count="1" label="infliximab"/><FilterOption id="78759" count="1" label="infliximab biosimilar, Celltrion/Nippon Kayaku/Hospira/Orion/EGIS Gyogyszergyar"/><FilterOption id="35644" count="1" label="methoxy polyethylene glycol-epoetin beta"/><FilterOption id="11519" count="1" label="mitoxantrone"/><FilterOption id="3648" count="1" label="molgramostim"/><FilterOption id="12978" count="1" label="moxifloxacin"/><FilterOption id="9000" count="1" label="onabotulinumtoxinA"/><FilterOption id="45817" count="1" label="paricalcitol (oral), Abbott"/><FilterOption id="43738" count="1" label="pazopanib"/><FilterOption id="5968" count="1" label="reslizumab"/><FilterOption id="86582" count="1" label="RG-7745"/><FilterOption id="49398" count="1" label="sevelamer carbonate (tablet, renal disease/hyperphosphatemia), Genzyme"/><FilterOption id="8713" count="1" label="sildenafil citrate"/><FilterOption id="54730" count="1" label="sotatercept"/><FilterOption id="12973" count="1" label="sunitinib"/><FilterOption id="6259" count="1" label="tocilizumab (intravenous), Roche/Chugai"/><FilterOption id="42858" count="1" label="ustekinumab"/><FilterOption id="12406" count="1" label="vedolizumab"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="2622" count="4" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="2492" count="3" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="2619" count="3" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"/><FilterOption id="2703" count="2" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="2704" count="2" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)"/><FilterOption id="6309" count="2" label="Crohns disease - Assessment of Clinical Response"/><FilterOption id="6471" count="2" label="Crohns disease - Protocol Specified Other Endpoints"/><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"/><FilterOption id="22596" count="2" label="End stage renal disease - Assessment of Mortality/Death Rates"/><FilterOption id="22552" count="2" label="End stage renal disease - Assessment of Serum Electrolytes - Assessment of phosphate"/><FilterOption id="7367" count="2" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7374" count="2" label="Multiple myeloma - Assessment of Therapy Related Outcomes"/><FilterOption id="7089" count="2" label="Prostate tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="15888" count="2" label="Ulcerative colitis - Assessment of Remission - Assessment of clinical remission"/><FilterOption id="15894" count="2" label="Ulcerative colitis - Assessment of Remission - Assessment of proportion of patients in remission"/><FilterOption id="15936" count="2" label="Ulcerative colitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="15971" count="2" label="Ulcerative colitis - Protocol Specified Other Endpoints"/><FilterOption id="15907" count="2" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="3082" count="1" label="Acute coronary syndrome - Assessment of Stents Related Events"/><FilterOption id="17267" count="1" label="Anemia - Assessment of Co-morbidity - Assessment of cardiac diseases/disorders"/><FilterOption id="17363" count="1" label="Anemia - Assessment of Mortality/Death Rates"/><FilterOption id="17334" count="1" label="Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="17356" count="1" label="Anemia - Assessment of adverse events"/><FilterOption id="17294" count="1" label="Anemia - Hematological Assessments - Assessment of hemoglobin response"/><FilterOption id="5985" count="1" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"/><FilterOption id="5986" count="1" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"/><FilterOption id="5941" count="1" label="Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1"/><FilterOption id="6005" count="1" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide"/><FilterOption id="6000" count="1" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Blood eosinophils"/><FilterOption id="6083" count="1" label="Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="6110" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma Quality of Life Questionnaire (AQLQ)"/><FilterOption id="6111" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)"/><FilterOption id="27645" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control test (ACT)"/><FilterOption id="9492" count="1" label="Atrial fibrillation - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction"/><FilterOption id="9510" count="1" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"/><FilterOption id="9509" count="1" label="Atrial fibrillation - Assessment of Hemorrhagic Complications"/><FilterOption id="9437" count="1" label="Atrial fibrillation - Assessment of Mortality/Death Rates"/><FilterOption id="9519" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"/><FilterOption id="9676" count="1" label="Atrial fibrillation - Protocol Specified Other Endpoints - Assessment of prescription changes/rescue medication uses"/><FilterOption id="977" count="1" label="Cardiac failure - Assessment of Mortality/Death Rates - Assessment of in-hospital mortality"/><FilterOption id="819" count="1" label="Cardiac failure - Assessment of hospitalization"/><FilterOption id="4467" count="1" label="Chronic obstructive pulmonary disease - Assessment of hospitalization - Assessment of Hospitalization Rates"/><FilterOption id="4468" count="1" label="Chronic obstructive pulmonary disease - Assessment of hospitalization - Readmission/time to readmission"/><FilterOption id="2664" count="1" label="Coronary artery disease - Assessment of Artery Plaque /Atheroma - Vessel Lumen Patency/Change in lumen area and volume"/><FilterOption id="2491" count="1" label="Coronary artery disease - Assessment of Cardiovascular Events"/><FilterOption id="2667" count="1" label="Coronary artery disease - Assessment of Procedure and Procedure Related Events - Coronary Angiography"/><FilterOption id="43282" count="1" label="Coronary artery disease - Assessment of Safety and Tolerability"/><FilterOption id="2551" count="1" label="Coronary artery disease - Assessment of Stenosis/Restenosis - In-segment late loss/In-lesion late loss"/><FilterOption id="2749" count="1" label="Coronary artery disease - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment"/><FilterOption id="2565" count="1" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis"/><FilterOption id="26220" count="1" label="Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)"/><FilterOption id="26311" count="1" label="Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)"/><FilterOption id="26218" count="1" label="Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="6368" count="1" label="Crohns disease - Assessment of Biomarkers"/><FilterOption id="6451" count="1" label="Crohns disease - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="6320" count="1" label="Crohns disease - Assessment of Remission - Proportion of patients achieving clinical remission"/><FilterOption id="6447" count="1" label="Crohns disease - Assessment of Safety and Tolerability - Assessment of serious adverse events"/><FilterOption id="6439" count="1" label="Crohns disease - Assessment of Safety and Tolerability"/><FilterOption id="6429" count="1" label="Crohns disease - Assessment of Therapy Related Outcomes"/><FilterOption id="6433" count="1" label="Crohns disease - Assessment of use of Rescue Medication"/><FilterOption id="6351" count="1" label="Crohns disease - Crohn's Disease Activity Assessed by Capsule Endoscopy/Endoscopy"/><FilterOption id="6407" count="1" label="Crohns disease - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="11433" count="1" label="Diabetic complication - Assessment of Best Corrected Visual Acuity"/><FilterOption id="11262" count="1" label="Diabetic complication - Assessment of Renal Function - Urinary albumin to creatinine ratio (UACR)"/><FilterOption id="30486" count="1" label="Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="22563" count="1" label="End stage renal disease - Anthropometric Assessments"/><FilterOption id="22532" count="1" label="End stage renal disease - Assessment of Biomarkers - Assessment of other inflammatory/oxidative stress markers"/><FilterOption id="22587" count="1" label="End stage renal disease - Assessment of Disease Progression"/><FilterOption id="22506" count="1" label="End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)"/><FilterOption id="22548" count="1" label="End stage renal disease - Assessment of Hormone Levels - Assessment of Parathyroid hormone (PTH)"/><FilterOption id="22561" count="1" label="End stage renal disease - Assessment of Laboratory/Diagnostic Measures - Assessment of vitamin status"/><FilterOption id="22564" count="1" label="End stage renal disease - Assessment of Nutritional Status - Assessment of other nutritional markers"/><FilterOption id="22592" count="1" label="End stage renal disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="22593" count="1" label="End stage renal disease - Assessment of Safety and Tolerability"/><FilterOption id="22507" count="1" label="End stage renal disease - Assessment of Serum Creatinine"/><FilterOption id="22553" count="1" label="End stage renal disease - Assessment of Serum Electrolytes - Assessment of calcium"/><FilterOption id="22577" count="1" label="End stage renal disease - Assessment of Transplantation"/><FilterOption id="22511" count="1" label="End stage renal disease - Assessment of Urinary Protein Excretion/Proteinuria - Assessment of proteinuria/albuminuria/macroalbuminuria"/><FilterOption id="22595" count="1" label="End stage renal disease - Assessment of adverse events"/><FilterOption id="22570" count="1" label="End stage renal disease - Assessment of dialysis"/><FilterOption id="22543" count="1" label="End stage renal disease - Assessment of lipid profiles"/><FilterOption id="22545" count="1" label="End stage renal disease - Hematological Assessments - Assessment of hemoglobin levels"/><FilterOption id="12048" count="1" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"/><FilterOption id="16838" count="1" label="Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity"/><FilterOption id="9247" count="1" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="9255" count="1" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="76" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Ambulatory diastolic blood pressure (ADBP)"/><FilterOption id="61" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Ambulatory systolic blood pressure (ASBP)"/><FilterOption id="46" count="1" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP)"/><FilterOption id="5" count="1" label="Hypertension - Assessment of Blood Pressure (BP) - Clinic/office BP"/><FilterOption id="6" count="1" label="Hypertension - Assessment of Blood Pressure (BP) - Home BP"/><FilterOption id="32" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - DBP control rate"/><FilterOption id="40" count="1" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"/><FilterOption id="99" count="1" label="Hypertension - Assessment of Pulse Pressure"/><FilterOption id="44798" count="1" label="Inflammatory bowel disease - Assessment of Biomarkers"/><FilterOption id="16174" count="1" label="Influenza virus infection - Assessment of Immune Response"/><FilterOption id="16181" count="1" label="Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity"/><FilterOption id="22153" count="1" label="Interstitial lung disease - Assessment of Forced Vital Capacity (FVC)"/><FilterOption id="22195" count="1" label="Interstitial lung disease - Assessment of Safety and Tolerability"/><FilterOption id="22196" count="1" label="Interstitial lung disease - Assessment of adverse events"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="94"><FilterOption id="14881" count="7" label="Boehringer Ingelheim International GmbH"/><FilterOption id="19446" count="7" label="Roche Holding AG"/><FilterOption id="22546" count="5" label="Boehringer Ingelheim GmbH"/><FilterOption id="1103352" count="4" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"/><FilterOption id="22563" count="4" label="Boehringer Ingelheim Ltd"/><FilterOption id="27741" count="4" label="Galapagos NV"/><FilterOption id="16450" count="4" label="Gilead Sciences Inc"/><FilterOption id="1143376" count="4" label="Gilead Sciences Singapore Pte Ltd"/><FilterOption id="1076492" count="4" label="HOSPITAL DE GALDACANO"/><FilterOption id="1038736" count="4" label="PETHEMA Foundation"/><FilterOption id="22545" count="3" label="Boehringer Ingelheim AB"/><FilterOption id="18767" count="3" label="Pfizer Inc"/><FilterOption id="1122528" count="3" label="SCS Boehringer Ingelheim Comm.V"/><FilterOption id="13601" count="2" label="Abbott Laboratories"/><FilterOption id="22556" count="2" label="Boehringer Ingelheim France SARL"/><FilterOption id="22590" count="2" label="Boehringer Ingelheim SA"/><FilterOption id="15331" count="2" label="Celgene Corp"/><FilterOption id="1069026" count="2" label="Effice Servicios Para la Investigacion"/><FilterOption id="26178" count="2" label="F Hoffmann-La Roche AG"/><FilterOption id="19453" count="2" label="Genentech Inc"/><FilterOption id="1069025" count="2" label="Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa"/><FilterOption id="1039423" count="2" label="Hospital Clinic of Barcelona"/><FilterOption id="1079012" count="2" label="Hospital de Galdakao"/><FilterOption id="1017818" count="2" label="Instituto de Salud Carlos III"/><FilterOption id="1099505" count="2" label="Osakidetza"/><FilterOption id="1077534" count="2" label="Sociedad Española de Neumología y Cirugía Torácica"/><FilterOption id="13626" count="1" label="Abbott Laboratories Ltd"/><FilterOption id="1061163" count="1" label="Abbott Vascular"/><FilterOption id="1066960" count="1" label="Adverum Biotechnologies Inc"/><FilterOption id="14042" count="1" label="Allergan Inc"/><FilterOption id="14109" count="1" label="Amgen Inc"/><FilterOption id="1012397" count="1" label="Arisaph Pharmaceuticals Inc"/><FilterOption id="31524" count="1" label="Asahi Intecc Co Ltd"/><FilterOption id="20972" count="1" label="Astellas Pharma Europe Ltd"/><FilterOption id="1013295" count="1" label="Astellas Pharma Inc"/><FilterOption id="1158336" count="1" label="AstraZeneca AB, spain"/><FilterOption id="14190" count="1" label="AstraZeneca plc"/><FilterOption id="14438" count="1" label="Baxter Healthcare Corp"/><FilterOption id="14455" count="1" label="Bayer AG"/><FilterOption id="1094314" count="1" label="Biosensors Europe SA"/><FilterOption id="1016827" count="1" label="Biosensors International Group Ltd"/><FilterOption id="1018917" count="1" label="Biotronik VI Patent AG"/><FilterOption id="22553" count="1" label="Boehringer Ingelheim A/S"/><FilterOption id="22549" count="1" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="22554" count="1" label="Boehringer Ingelheim BV"/><FilterOption id="22586" count="1" label="Boehringer Ingelheim Corp"/><FilterOption id="22555" count="1" label="Boehringer Ingelheim Ellas AE"/><FilterOption id="22560" count="1" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="15065" count="1" label="Bristol-Myers Squibb Co"/><FilterOption id="1017506" count="1" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1077096" count="1" label="EuroCTO Club"/><FilterOption id="1086388" count="1" label="foundation Senefro"/><FilterOption id="1053612" count="1" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="1093964" count="1" label="Fundacion Interhospitalaria para la Investigacion Cardiovascular"/><FilterOption id="1046327" count="1" label="Fundacion Renal Inigo Alvarez De Toledo"/><FilterOption id="1161122" count="1" label="Fundación EPIC"/><FilterOption id="1064566" count="1" label="Fundación Instituto De Estudios De Ciencias De La Salud De Castilla Y León"/><FilterOption id="1082416" count="1" label="Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular"/><FilterOption id="1051308" count="1" label="Fundación Para La Investigación Biomédica Del Hospital De La Princesa"/><FilterOption id="1024529" count="1" label="Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañon"/><FilterOption id="1042252" count="1" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="1010293" count="1" label="Hospira Inc"/><FilterOption id="1131033" count="1" label="Hospital Costa del Sol"/><FilterOption id="1164375" count="1" label="Hospital de Antequera"/><FilterOption id="1059304" count="1" label="Hospital de Basurto"/><FilterOption id="1080926" count="1" label="Hospital de Sabadell"/><FilterOption id="1040862" count="1" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="1164374" count="1" label="Hospital Santa Marina"/><FilterOption id="1040940" count="1" label="Hospital Universitari de Bellvitge"/><FilterOption id="1051496" count="1" label="Hospital Universitario Donostia"/><FilterOption id="1044505" count="1" label="Hospital Universitario de Canarias"/><FilterOption id="1058215" count="1" label="Hospital Universitario de La Princesa"/><FilterOption id="1086209" count="1" label="Hospital Valme"/><FilterOption id="1168890" count="1" label="Instituto de Investigación Biomédica de Salamanca"/><FilterOption id="1119275" count="1" label="Instituto de Investigación Sanitaria Hospital Universitario de La Princesa"/><FilterOption id="17332" count="1" label="Johnson &amp; Johnson"/><FilterOption id="1153001" count="1" label="Klinera Corporation India"/><FilterOption id="18077" count="1" label="Merck &amp; Co Inc"/><FilterOption id="1055006" count="1" label="Ministry of Health, Spain"/><FilterOption id="1054113" count="1" label="National Health Service"/><FilterOption id="1048099" count="1" label="Queen Mary Hospital"/><FilterOption id="1003618" count="1" label="Reata Pharmaceuticals Inc"/><FilterOption id="1090417" count="1" label="Roche Singapore Pte Ltd"/><FilterOption id="16299" count="1" label="Sanofi Genzyme"/><FilterOption id="1053159" count="1" label="Spanish Foundation of Rheumatology"/><FilterOption id="1073757" count="1" label="Spanish Society of Cardiology"/><FilterOption id="28185" count="1" label="St Jude Medical Inc"/><FilterOption id="20300" count="1" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="20341" count="1" label="Terumo Corp"/><FilterOption id="1044204" count="1" label="Terumo Europe NV"/><FilterOption id="29076" count="1" label="Teva Pharmaceuticals USA Inc"/><FilterOption id="1114403" count="1" label="TFS Trial Form Support"/><FilterOption id="22598" count="1" label="Unilfarma Lda"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="53"><FilterOption count="3" label="2019-06-13"/><FilterOption count="3" label="2019-06-26"/><FilterOption count="2" label="2018-10-13"/><FilterOption count="2" label="2019-01-25"/><FilterOption count="2" label="2019-01-26"/><FilterOption count="2" label="2019-02-06"/><FilterOption count="2" label="2019-03-27"/><FilterOption count="2" label="2019-07-03"/><FilterOption count="1" label="2014-01-22"/><FilterOption count="1" label="2014-09-09"/><FilterOption count="1" label="2015-11-16"/><FilterOption count="1" label="2015-12-04"/><FilterOption count="1" label="2016-07-07"/><FilterOption count="1" label="2016-07-15"/><FilterOption count="1" label="2016-09-28"/><FilterOption count="1" label="2017-04-12"/><FilterOption count="1" label="2017-05-30"/><FilterOption count="1" label="2017-09-11"/><FilterOption count="1" label="2017-11-20"/><FilterOption count="1" label="2018-03-16"/><FilterOption count="1" label="2018-05-19"/><FilterOption count="1" label="2018-06-09"/><FilterOption count="1" label="2018-06-13"/><FilterOption count="1" label="2018-06-23"/><FilterOption count="1" label="2018-07-13"/><FilterOption count="1" label="2018-10-15"/><FilterOption count="1" label="2018-10-31"/><FilterOption count="1" label="2018-11-12"/><FilterOption count="1" label="2018-12-13"/><FilterOption count="1" label="2018-12-27"/><FilterOption count="1" label="2019-01-09"/><FilterOption count="1" label="2019-01-24"/><FilterOption count="1" label="2019-02-10"/><FilterOption count="1" label="2019-02-22"/><FilterOption count="1" label="2019-03-03"/><FilterOption count="1" label="2019-03-05"/><FilterOption count="1" label="2019-03-26"/><FilterOption count="1" label="2019-03-30"/><FilterOption count="1" label="2019-04-09"/><FilterOption count="1" label="2019-04-10"/><FilterOption count="1" label="2019-04-15"/><FilterOption count="1" label="2019-05-04"/><FilterOption count="1" label="2019-05-07"/><FilterOption count="1" label="2019-05-11"/><FilterOption count="1" label="2019-05-16"/><FilterOption count="1" label="2019-05-23"/><FilterOption count="1" label="2019-05-31"/><FilterOption count="1" label="2019-06-07"/><FilterOption count="1" label="2019-06-14"/><FilterOption count="1" label="2019-06-19"/><FilterOption count="1" label="2019-06-20"/><FilterOption count="1" label="2019-06-21"/><FilterOption count="1" label="2019-06-27"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="50"><FilterOption count="3" label="202012"/><FilterOption count="2" label="200812"/><FilterOption count="2" label="201607"/><FilterOption count="2" label="201707"/><FilterOption count="2" label="201712"/><FilterOption count="2" label="201812"/><FilterOption count="2" label="201908"/><FilterOption count="2" label="201912"/><FilterOption count="2" label="202210"/><FilterOption count="1" label="200203"/><FilterOption count="1" label="200404"/><FilterOption count="1" label="200608"/><FilterOption count="1" label="200701"/><FilterOption count="1" label="200712"/><FilterOption count="1" label="200909"/><FilterOption count="1" label="200912"/><FilterOption count="1" label="201206"/><FilterOption count="1" label="201212"/><FilterOption count="1" label="201306"/><FilterOption count="1" label="201307"/><FilterOption count="1" label="201308"/><FilterOption count="1" label="201312"/><FilterOption count="1" label="201401"/><FilterOption count="1" label="201406"/><FilterOption count="1" label="201408"/><FilterOption count="1" label="201409"/><FilterOption count="1" label="201608"/><FilterOption count="1" label="201610"/><FilterOption count="1" label="201704"/><FilterOption count="1" label="201706"/><FilterOption count="1" label="201711"/><FilterOption count="1" label="201802"/><FilterOption count="1" label="201804"/><FilterOption count="1" label="201806"/><FilterOption count="1" label="201810"/><FilterOption count="1" label="201811"/><FilterOption count="1" label="201901"/><FilterOption count="1" label="201903"/><FilterOption count="1" label="201904"/><FilterOption count="1" label="201910"/><FilterOption count="1" label="202002"/><FilterOption count="1" label="202006"/><FilterOption count="1" label="202011"/><FilterOption count="1" label="202101"/><FilterOption count="1" label="202103"/><FilterOption count="1" label="202105"/><FilterOption count="1" label="202107"/><FilterOption count="1" label="202207"/><FilterOption count="1" label="202208"/><FilterOption count="1" label="202411"/></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="57"><FilterOption count="2" label="201311"/><FilterOption count="2" label="201405"/><FilterOption count="2" label="201610"/><FilterOption count="2" label="201611"/><FilterOption count="2" label="201810"/><FilterOption count="2" label="201904"/><FilterOption count="1" label="199606"/><FilterOption count="1" label="199810"/><FilterOption count="1" label="200003"/><FilterOption count="1" label="200105"/><FilterOption count="1" label="200106"/><FilterOption count="1" label="200210"/><FilterOption count="1" label="200503"/><FilterOption count="1" label="200510"/><FilterOption count="1" label="200601"/><FilterOption count="1" label="200603"/><FilterOption count="1" label="200707"/><FilterOption count="1" label="200804"/><FilterOption count="1" label="200806"/><FilterOption count="1" label="200812"/><FilterOption count="1" label="200901"/><FilterOption count="1" label="200904"/><FilterOption count="1" label="200907"/><FilterOption count="1" label="201003"/><FilterOption count="1" label="201005"/><FilterOption count="1" label="201106"/><FilterOption count="1" label="201201"/><FilterOption count="1" label="201202"/><FilterOption count="1" label="201204"/><FilterOption count="1" label="201205"/><FilterOption count="1" label="201207"/><FilterOption count="1" label="201301"/><FilterOption count="1" label="201310"/><FilterOption count="1" label="201404"/><FilterOption count="1" label="201407"/><FilterOption count="1" label="201411"/><FilterOption count="1" label="201504"/><FilterOption count="1" label="201506"/><FilterOption count="1" label="201508"/><FilterOption count="1" label="201601"/><FilterOption count="1" label="201602"/><FilterOption count="1" label="201605"/><FilterOption count="1" label="201606"/><FilterOption count="1" label="201607"/><FilterOption count="1" label="201612"/><FilterOption count="1" label="201701"/><FilterOption count="1" label="201702"/><FilterOption count="1" label="201703"/><FilterOption count="1" label="201704"/><FilterOption count="1" label="201711"/><FilterOption count="1" label="201802"/><FilterOption count="1" label="201806"/><FilterOption count="1" label="201812"/><FilterOption count="1" label="201902"/><FilterOption count="1" label="201903"/><FilterOption count="1" label="201906"/><FilterOption count="1" label="201907"/></Filter><Filter label="Trial Phase" name="trialPhase" total="7"><FilterOption id="C4" count="23" label="Phase 4 Clinical"/><FilterOption id="C3" count="18" label="Phase 3 Clinical"/><FilterOption id="PNA" count="10" label="Phase Not Applicable"/><FilterOption id="C2" count="6" label="Phase 2 Clinical"/><FilterOption id="NS" count="3" label="Phase not specified"/><FilterOption id="C3B" count="2" label="Phase 3b Clinical"/><FilterOption id="C23" count="1" label="Phase 2/Phase 3 Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="1169" count="4" label="Coronary artery disease - Subjects with History of /Scheduled for Coronary Revascularization Therapy"/><FilterOption id="584" count="4" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"/><FilterOption id="3248" count="3" label="Crohns disease - Protocol Specified Other Inclusion Criteria"/><FilterOption id="3537" count="3" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3538" count="3" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3539" count="3" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="14436" count="2" label="Anemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of rHuEPO therapy"/><FilterOption id="14362" count="2" label="Anemia - Subjects with History/Scheduled for Surgery/Intervention - Subjects received/scheduled for hemodialysis"/><FilterOption id="14493" count="2" label="Anemia - Subjects with Normal/Acceptable Hemoglobin Count"/><FilterOption id="14432" count="2" label="Anemia - Subjects with Normal/Acceptable Laboratory Criteria - Subjects with normal/acceptable iron levels"/><FilterOption id="22366" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma"/><FilterOption id="5579" count="2" label="Atrial fibrillation - Subjects with Nonvalvular Atrial Fibrillation"/><FilterOption id="22348" count="2" label="Chronic obstructive pulmonary disease - Subjects with Abnormal Pulmonary Function Parameters - Subjects with abnormal/required FEV1 levels"/><FilterOption id="1205" count="2" label="Coronary artery disease - Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD - De novo lesion/lesions"/><FilterOption id="1249" count="2" label="Coronary artery disease - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="3253" count="2" label="Crohns disease - Subjects with Protocol Specified Reproductive Status - Women with adequate contraception/Negative pregnancy test/Non-lactating women"/><FilterOption id="3201" count="2" label="Crohns disease - Treatment Naive Subjects - Biologic therapy naive subjects"/><FilterOption id="7034" count="2" label="Diabetic complication - Protocol Specified Other Inclusion Criteria"/><FilterOption id="6954" count="2" label="Diabetic complication - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"/><FilterOption id="17676" count="2" label="End stage renal disease - Subjects with Anemia of Chronic Kidney Disease"/><FilterOption id="17652" count="2" label="End stage renal disease - Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD) - Subjects with stage 5 CKD/end stage renal disease(ESRD)"/><FilterOption id="17678" count="2" label="End stage renal disease - Subjects with Electrolyte Imbalance/Associated Complications"/><FilterOption id="17694" count="2" label="End stage renal disease - Subjects with History of/Scheduled to Receive Therapy - Subjects on erythropoietin/iron supplements"/><FilterOption id="17692" count="2" label="End stage renal disease - Subjects with History of/Scheduled to Receive Therapy - Subjects on renin-angiotensin-aldosterone system(RAAS) blockers"/><FilterOption id="17644" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 4 chronic kidney disease"/><FilterOption id="91" count="2" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy - Subjects not responding to treatment"/><FilterOption id="80" count="2" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy - Subjects on monotherapy"/><FilterOption id="82" count="2" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy - Subjects on triple combination therapy"/><FilterOption id="81" count="2" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy - Subjects on two-drug combination therapy"/><FilterOption id="79" count="2" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="5" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with mild/stage 1 (JNC 6) hypertension"/><FilterOption id="1" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension"/><FilterOption id="21" count="2" label="Hypertension - Subjects with Treatment Resistant Disease"/><FilterOption id="19654" count="2" label="Interstitial lung disease - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="19661" count="2" label="Interstitial lung disease - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="3548" count="2" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"/><FilterOption id="3447" count="2" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="3448" count="2" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="3464" count="2" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"/><FilterOption id="3475" count="2" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with indolent (slow-growing, low grade) lymphoma"/><FilterOption id="4628" count="2" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum M-protein"/><FilterOption id="4630" count="2" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum/urine light chain"/><FilterOption id="4672" count="2" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological status"/><FilterOption id="4685" count="2" label="Multiple myeloma - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of =/&gt;3 months"/><FilterOption id="4691" count="2" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4692" count="2" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4676" count="2" label="Multiple myeloma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4601" count="2" label="Multiple myeloma - Subjects with Symptomatic Disease"/><FilterOption id="1061" count="2" label="Non-insulin dependent diabetes - Protocol Specified Other Inclusion Criteria - Study specific protocol requirements"/><FilterOption id="1042" count="2" label="Non-insulin dependent diabetes - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="3755" count="2" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"/><FilterOption id="3709" count="2" label="Prostate tumor - Subjects with Progressive Prostate Cancer - Subjects with progressive disease despite therapy"/><FilterOption id="3762" count="2" label="Prostate tumor - Treatment Refractory Prostate Cancer Subjects"/><FilterOption id="15853" count="2" label="Ulcerative colitis - Protocol Specified Other Inclusion Criteria - Other protocol specified inclusion criteria"/><FilterOption id="15781" count="2" label="Ulcerative colitis - Subjects Included Based on Disease Activity Scores - Subjects enrolled based on Mayo score/disease activity index/MMDAI"/><FilterOption id="15780" count="2" label="Ulcerative colitis - Subjects Included Based on Disease Activity Scores"/><FilterOption id="15774" count="2" label="Ulcerative colitis - Subjects with Active Ulcerative Colitis"/><FilterOption id="15811" count="2" label="Ulcerative colitis - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="15828" count="2" label="Ulcerative colitis - Subjects with Normal/Acceptable Laboratory Criteria - Subjects assessed by/indicated for endoscopic examination"/><FilterOption id="15846" count="2" label="Ulcerative colitis - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="15810" count="2" label="Ulcerative colitis - Treatment Naive Subjects"/><FilterOption id="1285" count="1" label="Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects"/><FilterOption id="1352" count="1" label="Acute coronary syndrome - Subjects with Abnormal Coronary Angiographic Findings"/><FilterOption id="1274" count="1" label="Acute coronary syndrome - Subjects with Acute Myocardial Infarction"/><FilterOption id="1321" count="1" label="Acute coronary syndrome - Subjects with History of/Scheduled for Cardiac Surgery/Intervention"/><FilterOption id="14360" count="1" label="Anemia - Subjects with Anemia of Renal Disease"/><FilterOption id="14451" count="1" label="Anemia - Subjects with History of/Scheduled for Therapy for other Indication"/><FilterOption id="14423" count="1" label="Anemia - Subjects with Normal/Acceptable Clinical Assessments"/><FilterOption id="14425" count="1" label="Anemia - Subjects with Protocol Specified Anthropometric Measurements"/><FilterOption id="14400" count="1" label="Anemia - Subjects with Symptomatic Disease"/><FilterOption id="14434" count="1" label="Anemia - Treatment Naive Subjects"/><FilterOption id="2801" count="1" label="Asthma - Bronchial Hyper Responsiveness by Methacholine Challenge Test"/><FilterOption id="2875" count="1" label="Asthma - Protocol Specified Other Inclusion Criteria"/><FilterOption id="2799" count="1" label="Asthma - Subjects with Bronchial Reversibility Post Bronchodilator Administration - Increase in FEV1 &gt; 12% or 200ml"/><FilterOption id="2773" count="1" label="Asthma - Subjects with FEV1 Measurement"/><FilterOption id="22368" count="1" label="Asthma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for asthma drugs"/><FilterOption id="2720" count="1" label="Asthma - Subjects with Levels of Asthma Control - Subjects with uncontrolled asthma"/><FilterOption id="2849" count="1" label="Asthma - Subjects with Other Abnormal Lab Parameters"/><FilterOption id="33515" count="1" label="Asthma - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="5658" count="1" label="Atrial fibrillation - Protocol Specified Other Inclusion Criteria"/><FilterOption id="5558" count="1" label="Atrial fibrillation - Subjects at Risk of Developing Disease - Subjects with coronary artery disease"/><FilterOption id="5634" count="1" label="Atrial fibrillation - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="5664" count="1" label="Atrial fibrillation - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="447" count="1" label="Cardiac failure - Protocol Specified Other Inclusion Criteria"/><FilterOption id="33672" count="1" label="Cardiac failure - Subjects Fulfilling Protocol Specific Diagnostic Criteria"/><FilterOption id="271" count="1" label="Cardiac failure - Subjects with Acute/Sub Acute Heart Failure"/><FilterOption id="272" count="1" label="Cardiac failure - Subjects with Chronic Heart Failure"/><FilterOption id="312" count="1" label="Cardiac failure - Subjects with Clinical Features Suggestive of Heart Failure - Pulmonary congestion"/><FilterOption id="261" count="1" label="Cardiac failure - Subjects with Decompensated Heart Failure"/><FilterOption id="315" count="1" label="Cardiac failure - Subjects with History of Hospitalization"/><FilterOption id="485" count="1" label="Cardiac failure - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="307" count="1" label="Cardiac failure - Subjects with Symptomatic Disease - Subjects with fatigue as a symptom of main disease"/><FilterOption id="2171" count="1" label="Chronic obstructive pulmonary disease - Protocol Specified Other Inclusion Criteria"/><FilterOption id="2072" count="1" label="Chronic obstructive pulmonary disease - Subjects with Breathlessness"/><FilterOption id="2200" count="1" label="Chronic obstructive pulmonary disease - Subjects with Cough/Sputum Production"/><FilterOption id="2064" count="1" label="Chronic obstructive pulmonary disease - Subjects with Diagnosis of COPD - Subjects with stable COPD"/><FilterOption id="2063" count="1" label="Chronic obstructive pulmonary disease - Subjects with Diagnosis of COPD - Subjects with symptomatic COPD"/><FilterOption id="2060" count="1" label="Chronic obstructive pulmonary disease - Subjects with Diagnosis of COPD"/><FilterOption id="2105" count="1" label="Chronic obstructive pulmonary disease - Subjects with Exacerbations - Subjects with severe exacerbation requiring hospitalization"/><FilterOption id="2099" count="1" label="Chronic obstructive pulmonary disease - Subjects with Exacerbations"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="5"><FilterOption id="53547" count="1" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="2836" count="1" label="clopidogrel"/><FilterOption id="6850" count="1" label="infliximab"/><FilterOption id="4196" count="1" label="ramipril"/><FilterOption id="8050" count="1" label="thalidomide, Celgene"/></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="14"><FilterOption id="4913" count="2" label="P2Y12 purinoceptor antagonist"/><FilterOption id="76469" count="1" label="26S proteasome complex inhibitor"/><FilterOption id="18" count="1" label="ACE inhibitor"/><FilterOption id="12162" count="1" label="Erythropoietin ligand"/><FilterOption id="111" count="1" label="Factor IIa antagonist"/><FilterOption id="113" count="1" label="Factor IX antagonist"/><FilterOption id="114" count="1" label="Factor VII antagonist"/><FilterOption id="119" count="1" label="Factor X antagonist"/><FilterOption id="15904" count="1" label="Placenta growth factor ligand inhibitor"/><FilterOption id="4917" count="1" label="Proteasome inhibitor"/><FilterOption id="381" count="1" label="TNF alpha ligand inhibitor"/><FilterOption id="721" count="1" label="TNF binding agent"/><FilterOption id="1689" count="1" label="VEGF-A ligand inhibitor"/><FilterOption id="10583" count="1" label="Vitamin K epoxide reductase inhibitor"/></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="54"><FilterOption id="17" count="4" label="Anemia"/><FilterOption id="746" count="4" label="Infectious disease"/><FilterOption id="1991" count="4" label="Neutropenia"/><FilterOption id="3062" count="3" label="Death"/><FilterOption id="129" count="3" label="Gastrointestinal disease"/><FilterOption id="148" count="3" label="Headache"/><FilterOption id="224" count="3" label="Myocardial infarction"/><FilterOption id="324" count="3" label="Thrombocytopenia"/><FilterOption id="404" count="2" label="Constipation"/><FilterOption id="402" count="2" label="Edema"/><FilterOption id="2854" count="2" label="Ostealgia"/><FilterOption id="20" count="2" label="Pain"/><FilterOption id="259" count="2" label="Peripheral neuropathy"/><FilterOption id="2274" count="2" label="Rhinopharyngitis"/><FilterOption id="3038" count="1" label="Appetite loss"/><FilterOption id="2439" count="1" label="Arthralgia"/><FilterOption id="1543" count="1" label="Atrial flutter"/><FilterOption id="1875" count="1" label="Atrioventricular block"/><FilterOption id="3221" count="1" label="Back pain"/><FilterOption id="552" count="1" label="Bleeding"/><FilterOption id="1091" count="1" label="Bone injury"/><FilterOption id="50" count="1" label="Bronchitis"/><FilterOption id="55" count="1" label="Cardiac failure"/><FilterOption id="60" count="1" label="Central nervous system disease"/><FilterOption id="1559" count="1" label="Congestive heart failure"/><FilterOption id="82" count="1" label="Cough"/><FilterOption id="574" count="1" label="Deep vein thrombosis"/><FilterOption id="102" count="1" label="Diarrhea"/><FilterOption id="2400" count="1" label="Dyspnea"/><FilterOption id="3251" count="1" label="End stage renal disease"/><FilterOption id="2024" count="1" label="Erythema"/><FilterOption id="829" count="1" label="Fatigue"/><FilterOption id="3795" count="1" label="Febrile neutropenia"/><FilterOption id="1833" count="1" label="Fever"/><FilterOption id="626" count="1" label="Heart disease"/><FilterOption id="2291" count="1" label="Hematuria"/><FilterOption id="2757" count="1" label="Hydronephrosis"/><FilterOption id="178" count="1" label="Hypertension"/><FilterOption id="181" count="1" label="Hypokalemia"/><FilterOption id="668" count="1" label="Muscle weakness"/><FilterOption id="216" count="1" label="Musculoskeletal disease"/><FilterOption id="2440" count="1" label="Musculoskeletal pain"/><FilterOption id="3006" count="1" label="Nasal congestion"/><FilterOption id="226" count="1" label="Nausea"/><FilterOption id="1973" count="1" label="Palpitation"/><FilterOption id="1997" count="1" label="Progressive multifocal leukoencephalopathy"/><FilterOption id="277" count="1" label="Proteinuria"/><FilterOption id="477" count="1" label="Rhinitis"/><FilterOption id="65" count="1" label="Stroke"/><FilterOption id="325" count="1" label="Thromboembolism"/><FilterOption id="1076" count="1" label="Thrombosis"/><FilterOption id="2382" count="1" label="Urinary retention"/><FilterOption id="1009" count="1" label="Urinary tract infection"/><FilterOption id="2434" count="1" label="Vertigo"/></Filter></Filters><SearchResults><Trial Id="332164"><Indications><Indication>Anesthesia</Indication></Indications><CompaniesSponsor><Company>HOSPITAL DE GALDACANO</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-03-16T00:00:00Z</DateChangeLast><DateEnd>2018-02-20T00:00:00Z</DateEnd><DateStart>2016-01-30T00:00:00Z</DateStart><Identifiers><Identifier>01/16</Identifier><Identifier>NCT03461029</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BIS quatro alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>196</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Observational study in patients undergoing scheduled colonoscopy in endoscopy rooms of the Galdakao-&lt;b&gt;Usansolo&lt;/b&gt; Hospital. The investigators objectified the level of sedation that was performed in these procedures using Bispectral Index Monitoring...Patients ( n = 196) from the general population, residents in the geographical area corresponding to the Hospital Galdakao &lt;b&gt;Usansolo&lt;/b&gt;, who attended the endoscopy rooms. Were included to undergo a scheduled colonoscopy, either for monitoring, diagnostic or</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term></TermsDesign><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Bispectral Index Monitoring During Anesthesiologist - Directed Sedation in Scheduled Colonoscopies</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Iratxe Gonzalez Mendibil, MD</Name></ContactNames></Trial><Trial Id="208797"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Hospital de Galdakao</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-09-09T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02223533</Identifier><Identifier>SORK-2011111058</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>19Gx500-mm Pajunk InfiltraLong catheter alone</Intervention><Intervention>morphine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to compare the safety and efficacy of interfascial continuous wound infiltration of a local anaesthetic and intravenous opioids after laparoscopic colon surgery in  controlling postoperative pain. The primary outcome variables were verbal numeric pain scale (NRS) scores and amount of intravenous morphine used via patient controlled infusion.</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Multimodal Analgesia With Interfascial Continuous Wound Infiltration: A Randomized Clinical Trial</TitleDisplay><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sorkunde Telletxea, MD, PhD</Name></ContactNames></Trial><Trial Id="338422"><Indications><Indication>Cardiac failure</Indication></Indications><CompaniesCollaborator><Company>Hospital Costa del Sol</Company><Company>Hospital Santa Marina</Company><Company>Hospital Universitari de Bellvitge</Company><Company>Hospital Universitario Donostia</Company><Company>Hospital Universitario de Canarias</Company><Company>Hospital de Antequera</Company><Company>Hospital de Basurto</Company><Company>Hospital de Sabadell</Company></CompaniesCollaborator><CompaniesSponsor><Company>HOSPITAL DE GALDACANO</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-02-06T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2013111071</Identifier><Identifier>ESSIC</Identifier><Identifier>NCT03512704</Identifier><Identifier>PI12/01671</Identifier><Identifier>PI13/02230</Identifier></Identifiers><PatientCountEnrollment>2218</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This would be a multicenter, prospective, observational cohort study with one year follow-up after inclusion in the study. There were nine hospitals participating in this project: Hospital Universitario Basurto, Santa Marina, Donostia, and Galdakao-&lt;b&gt;Usansolo&lt;/b&gt;, Hospital de Antequera, Costa del Sol, Universitario de Canarias, Universitario Parc Tauli y Bellvitge. Patients with known chronic heart failure (or de novo diagnosed in the emergency department visit) attended in the emergency services of the participating</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Markers - Plasma B-type natriuretic peptide (BNP)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events - Cardiovascular intervention/surgery</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Clinical Symptoms - Assessment of arrhythmia</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Electrocardiography (ECG) Findings</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Liver Functions</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Mortality/Death Rates - Assessment of in-hospital mortality</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Non Cardiovascular Events - Assessment of cerebrovascular adverse events (Stroke/TIA)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Renal Dysfunction/Events</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of adverse events</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization - Assessment of rehospitalizations</EndpointIndex><EndpointIndex>Cardiac failure - Health Economic Assessments - Assessment of cost effectiveness</EndpointIndex><EndpointIndex>Cardiac failure - Health Economic Assessments - Health care resource utilization</EndpointIndex><EndpointIndex>Cardiac failure - Hematological Assessments</EndpointIndex><EndpointIndex>Cardiac failure - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Barthel Activities of Daily Living Index</EndpointIndex><EndpointIndex>Cardiac failure - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Cardiac failure - Patient Reported Outcomes/Quality of Life Assessments - Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)</EndpointIndex><EndpointIndex>Cardiac failure - Patient Reported Outcomes/Quality of Life Assessments - Minnesota living with heart failure(MLWHF) questionnaire</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Assessment of prescription changes/rescue medication uses</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Echocardiographic parameter - unspecified</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Laboratory assessment - unspecified parameters</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Morbidity</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Resuscitated cardiac arrest</EndpointIndex><EndpointIndex>Cardiac failure - Requirement of Ventilatory Support/Intervention - Assessment of requirement of mechanical ventilation</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ESSIC: Development of Clinical Prediction Rules and Health Services Research in Patients With Heart Failure</TitleDisplay><PatientSegmentTerms><PatientSegment>Cardiac failure - Acute Decompensated Heart Failure (ADHF) Subjects</PatientSegment><PatientSegment>Cardiac failure - Chronic Heart Failure Subjects</PatientSegment><PatientSegment>Cardiac failure - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Natriuretic peptides B</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>62 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Jose M Quintana, MD, PhD</Name></ContactNames></Trial><Trial Id="236460"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>Osakidetza</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-09-28T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2016-07-31T00:00:00Z</DateStart><Identifiers><Identifier>CEIC 16/2015</Identifier><Identifier>NCT02511080</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Spot-On alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to use Spot-on device to monitor the core body temperature during colon laparoscopic surgery and prevent non-therapeutic hypothermia.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efectiveness Of Spot-on To Prevent Inadvertent Perioperative Hypothermia And Their Consequences</TitleDisplay><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Saioa Riaño</Name><Name>saioa Riaño</Name><Name>unai Ortega</Name><Name>unai ortega</Name></ContactNames></Trial><Trial Id="254905"><Indications><Indication>Coronary artery disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>AstraZeneca AB, spain</Company><Company>AstraZeneca plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundacion Interhospitalaria para la Investigacion Cardiovascular</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-23T00:00:00Z</DateChangeLast><DateEnd>2019-04-24T00:00:00Z</DateEnd><DateStart>2016-02-25T00:00:00Z</DateStart><Identifiers><Identifier>2015-003621-33</Identifier><Identifier>ESR-15-10793</Identifier><Identifier>NCT02698618</Identifier><Identifier>PREDICT</Identifier></Identifiers><InterventionsControlDisplay><Intervention>clopidogrel alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>percutaneous coronary intervention alone</Intervention><Intervention>ticagrelor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to determine whether ticagrelor has a protective effect on microcirculation during percutaneous coronary interventions in patients with diabetes mellitus type II or in a pre-diabetic status. The primary hypothesis was that ticagrelor might be superior to clopidogrel in providing microcirculatory protection during PCI procedures in the same subgroup of patients. The secondary hypothesis was that ticagrelor treatment pre-PCI might improve microcirculatory parameters (lower</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Cardiac structure and function</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PREDICT: Protective Effect on the Coronary Microcirculation of Patients With Diabetes by Clopidogrel or Ticagrelor</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with heart disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Activated Clotting Time </BiomarkerName><BiomarkerName> Coronary flow reserve </BiomarkerName><BiomarkerName> Creatine Kinase, MB Form </BiomarkerName><BiomarkerName> Fractional Flow Reserve </BiomarkerName><BiomarkerName> Microcirculatory resistance index </BiomarkerName><BiomarkerName> Troponin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Alicia Quirós, PhD</Name><Name>Enrico Cerrato, MD</Name><Name>Javier Escaned, MD, PhD</Name><Name>José M de la Torre</Name><Name>José M de la Torre, MD, PhD</Name><Name>José R Rumoroso</Name><Name>José R Rumoroso, MD, PhD</Name></ContactNames></Trial><Trial Id="216315"><Indications><Indication>Resistant hypertension</Indication></Indications><CompaniesSponsor><Company>Terumo Europe NV</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Serbia</Country></Countries><DateChangeLast>2016-07-15T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2014-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02295683</Identifier><Identifier>T124E2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Iberis renal denervation system alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this study is to document safety and efficacy of renal sympathetic denervation treatment in patients with uncontrolled hypertension by using Iberis renal denervation system.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - Clinic/office BP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - Home BP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis - HTN Registry</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects on Hypertensive Treatment</PatientSegment><PatientSegment>Hypertension - Subjects with Refractory/Resistant/Uncontrolled Hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with type 2 diabetes mellitus</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Garcia, Dr.</Name><Name>Goicolea, Dr.</Name><Name>Goran Stankovic, Dr.</Name><Name>José Ramon Rumoroso, Dr.</Name><Name>Mauri, Dr.</Name><Name>Palop López, Dr.</Name><Name>Perez, Dr.</Name></ContactNames></Trial><Trial Id="348394"><Indications><Indication>Pneumonia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA gyrase inhibitor</Action><Action>Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial nucleic acid synthesis inhibitor</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacion Clinic per a la Recerca Biomédica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-05T00:00:00Z</DateChangeLast><DateEnd>2021-05-15T00:00:00Z</DateEnd><DateStart>2019-02-15T00:00:00Z</DateStart><Identifiers><Identifier>2017-001406-15</Identifier><Identifier>NAC-ATB</Identifier><Identifier>NCT03609099</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>moxifloxacin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>424</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is a non-inferiority, multicenter, prospective, double-blind, randomized clinical trial of two parallel-groups to evaluate the adequate duration of antibiotic treatment in community-acquired pneumonia with high risk class and adequate initial clinical response.</Teaser><TrialCategories><Category>Pathophysiology</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Response - Clinical failure</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pneumonia - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Pneumonia - Protocol Specified Other Endpoints - Antimicrobial usage</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response</TitleDisplay><PatientSegmentTerms><PatientSegment>Pneumonia - Subjects with Community Acquired Pneumonia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-11-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Adrian Ceccato, MD</Name><Name>Adrian Ceccato, MSD</Name><Name>David Garcia Cinca, Study Applicant</Name><Name>Inmaculada Alfageme, MD</Name><Name>Jordi Almirall, MD</Name><Name>Miquel Ferrer, MD</Name><Name>Pedro España, MD</Name><Name>Rosario Menéndez, MD</Name></ContactNames></Trial><Trial Id="91779"><Indications><Indication>Migraine</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Acetylcholine receptor antagonist</Action><Action>p130Cas associated protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antiarrhythmic agent</Action><Action>Antidepressant</Action><Action>Neuromuscular blocking agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drying</Technology><Technology>Formulation powder</Technology><Technology>Intradermal formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Peptide</Technology><Technology>Toxin</Technology></Technologies><CompaniesSponsor><Company>Allergan Inc</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Norway</Country><Country>Spain</Country><Country>UK</Country><Country>Sweden</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2018-11-12T00:00:00Z</DateChangeLast><DateEnd>2016-10-12T00:00:00Z</DateEnd><DateStart>2012-07-23T00:00:00Z</DateStart><Identifiers><Identifier>MAF/AGN/NS/CM/002</Identifier><Identifier>NCT01686581</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>onabotulinumtoxinA alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>641</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was an observational study to describe the long term use of onabotulinumtoxinA (Botox) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Pain - Assessment of Frequency of Pain Episodes</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Assessment of Health Services Utilization</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Migraine-Specific Quality of Life (MSQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Observational Study of Botox as Headache Prophylaxis for Chronic Migraine</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Migraine</PatientSegment><PatientSegment>Pain - Subjects with specific disease - Subjects with chronic migraine</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-10-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>50 Months</TrialDuration><NumberOfSites>77</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="326998"><Indications><Indication>Diabetic nephropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Chymase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Bayer AG</Company></CompaniesSponsor><Countries><Country>Finland</Country><Country>Sweden</Country><Country>Israel</Country><Country>Bulgaria</Country><Country>Germany</Country><Country>Italy</Country><Country>Spain</Country><Country>Denmark</Country></Countries><DateChangeLast>2019-06-13T00:00:00Z</DateChangeLast><DateEnd>2019-10-17T00:00:00Z</DateEnd><DateStart>2018-02-02T00:00:00Z</DateStart><Identifiers><Identifier>18933</Identifier><Identifier>2017-000656-26</Identifier><Identifier>BAY1142524/18933</Identifier><Identifier>CADA DIA</Identifier><Identifier>NCT03412006</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard of care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fulacimstat alone</Intervention><Intervention>standard of care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>147</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of the trial is to analyze safety and efficacy of the chymase inhibitor BAY-1142524 at a dose of 25 mg bid in comparison to placebo using a 6 months treatment period in type 2 diabetic patients with a clinical diagnosis of diabetic kidney disease. BAY-1142524 or placebo will be given on top of evidence-based standard of care for diabetic kidney disease. Primary objective is the analysis of first signs of efficacy as determined by favourable changes in urinary albumin creatinine ratio</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Renal Function - Urinary albumin to creatinine ratio (UACR)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CADA DIA: A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY-1142524 in Patients With Type 2 Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Nephropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Diabetic Complications</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic nephropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Urinary albumin to creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-10-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>28</NumberOfSites><ContactNames><Name>Bayer clinical Trails Contact</Name></ContactNames></Trial><Trial Id="386770"><Indications><Indication>Lung embolism</Indication></Indications><CompaniesCollaborator><Company>Sociedad Española de Neumología y Cirugía Torácica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ministry of Health, Spain</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-07-03T00:00:00Z</DateChangeLast><DateEnd>2021-07-30T00:00:00Z</DateEnd><DateStart>2019-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2019-000266-37</Identifier><Identifier>AIRE</Identifier><Identifier>NCT04003116</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard medical therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>conventional anticoagulant treatment alone</Intervention><Intervention>oxygen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The primary objective is to evaluate the efficacy of the treatment with supplementary oxygen added to conventional anticoagulant treatment in patients with intermediate-risk pulmonary embolism. The secondary objective is to evaluate the safety of the treatment with supplementary oxygen added to conventional anticoagulant treatment in patients with intermediate-risk pulmonary embolism.</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Thrombosis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>AIRE: Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism</TitleDisplay><PatientSegmentTerms><PatientSegment>Thrombosis - Subjects at risk of developing disease</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with pulmonary embolism</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Right ventricle/Left ventricle ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>David Jimenez</Name><Name>David Jiménez</Name><Name>David Jiménez, MD, PhD</Name><Name>Deisy Diana Barrios</Name><Name>José Luis Lobo</Name><Name>Leyre Chasco</Name><Name>Luis Jara-Palomares</Name><Name>Pedro Ruiz-Artacho</Name><Name>Raquel López-Reyes</Name></ContactNames></Trial></SearchResults></trialResultsOutput>